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Glycosylation is one of the most abundant post-translational modifications of 
proteins. Glycoproteins participate in virtually all aspects of cellular functions. 
ST6Gal I is a glycosyltransferase highly expressed by B and T cells. Here, we 
interrogated the role of ST6Gal I in viral specific B and T cell immune responses, 
as well as examined how loss of this enzyme impacted viral pathogenesis. 
 
First, to understand how loss of ST6Gal I expression impacted viral specific 
humoral responses, we infected ST6Gal I-/- mice with influenza virus. We 
discovered that loss of ST6Gal I expression results in both reduced influenza 
specific antibodies levels and decreased viral-specific antibody secreting cells 
numbers. Following influenza infection, mice that received ST6Gal I-/- B cells 
showed reduced influenza-specific IgM responses compared to mice that 
received wild-type B cells. These experiments demonstrated that the expression 
of ST6Gal I by B cells is required for optimal viral-specific humoral response. 
 
We further examined how loss of ST6Gal I expression impacted the anti-
influenza IgA response. We observed that immune ST6Gal I-/- mice displayed 
higher viral specific IgA levels and altered sialylation of IgG and IgA, which have 
been implicated in a human disease, IgA nephropathy. Moreover, ST6Gal I-/- 
mice exhibited increased immunoglobulin deposition in kidney glomeruli following 
influenza infection. These data suggest that ST6Gal I deficiency, together with 
influenza infection, may result in the initiation of a kidney disease. 
 
Finally, we examined how ST6Gal I expression regulated CD8 T cell responses. 
We discovered that ST6Gal I is differentially expressed during CD8 T cell 
activation. To understand its relevance, we infected ST6Gal I-/- mice and 
demonstrated that the early expansion of effector T cells was impaired in a cell 
intrinsic manner. Moreover, in the absence of ST6Gal I, the differentiation of CD8 
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T cells skewed towards memory precursor cells, whereas terminal effector cell 
expansion was impaired. Mechanistically, we identified delayed surface 
expression of IL-2Ralpha on ST6Gal I-/- CD8 T cells due to impaired IL-2/IL-2R 
signaling. These studies implicate that ST6Gal I expression enhances early 
proliferation of terminal effector CD8 T cells by promoting the rapid surface 
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BCR                                       B cell receptor 
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TCR                                       T cell receptor 
 
STAT5                                   Signal transducer and activator of transcription 5
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1. Adaptive immunity overview 
The immune system is comprised of multiple cellular players. These cells 
express a variety of cell surface and intracellular molecules, which cooperate in 
an elaborate and dynamic network to recognize and eliminate pathogenic 
microorganisms. There are two arms of the immune system distinguished 
temporally, functionally, and in their antigen specificity. The innate immune 
system is distinguished by the use of pattern recognition receptors 
(PRRs)(Mogensen, 2009). Cells expressing PRRs recognize and destroy 
insulting pathogens expressing pathogen associated molecular patterns 
(PAMPs). The innate response consists of effector cells such as granulocytes, 
natural killer (NK) cells, and phagocytes and represents the first line of host 
defense against invading pathogens, launching the inflammatory response 
following infection. In addition, phagocytes engulf pathogens and cellular debris 
and subsequently present protein antigens to T lymphocytes to initiate adaptive 
immune responses(Bonilla and Oettgen, 2010).   Importantly, the innate immune 
system differs functionally from the adaptive immune response in that it does not 
confer long-term immunity, or memory, to the host. The innate response behaves 
identically following re-infection with the same agent. The second arm of the 
immune system is the adaptive or acquired immune response. It provides the 
second line of defense, often taking days to respond following the onset of 
infection. The adaptive immune system is comprised of B and T lymphocytes, 
expressing a tremendous variety of antigen recognition receptors that recognize 
specific antigen--either unprocessed antigens in the case of B cells or processed 
antigen in complex with self-major histocompatibility complex (MHC), in the case 
of T cells(Bonilla and Oettgen, 2010; Cooper and Alder, 2006). The orchestration 
of B and T cells constitute a highly sophisticated biological response that enables 
the host to potentially recognize virtually any pathogenic agent. Following 
elimination of the pathogen, the adaptive immune system acquires 
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immunological memory, which can efficiently and quickly launch pathogen-
specific responses to prevent re-infection with the same agents.  
 
1.1 B and T cells 
Instructed by environmental cues, pluripotent hematopoietic stem cells in the 
bone marrow differentiate into common myeloid progenitors and common 
lymphoid progenitors, and further develop into myeloid cells and lymphocytes, 
respectively(Cooper and Alder, 2006). In the bone marrow, the commitment to 
the B cell lineage is controlled by transcription factors, such as PU.1, IKAROS, 
and PAX5(Fuxa and Skok, 2007; LeBien and Tedder, 2008). B cell progenitors 
undergo several distinct developmental stages to achieve complete development 
to resting naïve B cells and then exit the bone marrow to circulate in the 
periphery. Following antigen stimulation, the majority of B cells will proliferate, 
differentiate into plasma cells, or enter germinal center reactions following 
contact with T-dependent antigens. 
 
T lymphocytes also arise from common lymphoid progenitors in the bone marrow 
but must migrate to the thymus for further development, where they reach 
maturation under the control of Notch and other transcription factors(Jenkinson et 
al., 2006). Before T cells can exit the thymus to seed the periphery, they must 
pass strict quality control.  After T cells express a functional T cell receptors 
(TCR) on their surface, they will go through a process called positive selection, 
during which only those T cells that recognize self-MHC receive signals enabling 
their survival. T cells also undergo negative selection, where those T cells that 
bind to self-MHC with high affinity will be eliminated to prevent autoimmunity.  
 
During development in the thymus, T cells differentiate into two major 
subpopulations, distinguished by their surface expression of CD4 or CD8 
molecules. CD4 T cells are the master regulators of adaptive immune 
4 
 
responses(Zhu and Paul, 2008). Upon contact with cognate antigen in the 
context of MHC class II expressed by antigen presenting cells (APCs), which are 
dendritic cells, activated macrophages, and activated B cells, naïve CD4 T cells 
differentiate into Th1, Th2, or other recently identified subsets. T helper subsets 
are characterized by the secretion of specific cytokines, such as IFNγ or IL-4. The 
diverse subsets of CD4 helper T cells orchestrate both B cell and T cell response 
against a plethora of pathogenic agents. CD8 T cells, also called cytotoxic 
lymphocytes (CTLs), can recognize processed peptide presented by MHC class 
I, expressed by all nucleated cells(Williams and Bevan, 2007). After a virus 
infects host cells, it usurps host protein synthesis machinery to produce viral 
protein, and viral peptides will be presented on the cell surface in the context of 
appropriate MHC class I. CD8 T cells can recognize MHC I/viral peptide 
complex, and kill virally-infected cells by either secreting a pore-forming protein 
(perforin), and a series of proteases (granzymes), or up-regulating a tumor 
necrosis factor (FasL) to induce apoptosis in the targeted cells. Thus, CD8 T 
cells are critical against intracellular pathogen infections and tumors.  
 
1.2 Viral immunity 
1.2.1 LCMV 
Lymphocytic chriomeningitis virus (LCMV) is a member of the Arenaviridae 
family, causing acute or chronic infections of rodents(Buchmeier et al., 1980), the 
natural host. LCMV has a bisegmented, negative, enveloped, and single-
stranded RNA genome, and the virus replicates systemically within the 
host(Fazakerley et al., 1991). It is a well-established virus model for investigating 
virus-specific T and B cell responses(Botten et al., 2010).  During acute virus 
infection, a vigorous viral-specific CD8 T cells response is induced in lymphoid 
organs, and functional CD8 T cells are required for virus clearance (Asensio et 




Influenza virus belongs to Orthomyxoviridae family. It contains a segmented, 
negative, enveloped, and single-stranded RNA genome, causing an acute and 
contagious pulmonary disease(Cox et al., 2004; Nicholson, 1992). According to 
the antigenic differences of nucleoprotein and matrix protein, influenza viruses 
are categorized into three types: type A, B, C. Two major viral glycoproteins 
hemagglutinin (HA) and neuraminidase (NA) expressed on the virion surface 
mediate the binding and entry to target cells and the release of progeny virus 
from the infected cell, respectively(Cox et al., 2004). Influenza viruses are 
constantly undergoing antigenic mutations to escape from host adaptive 
immunity, especially humoral immunity, causing antigenic shift and antigenic drift. 
Influenza infection induces robust B cell responses, and vigorous viral-specific 
antibody production contributes to virus clearance(Gerhard et al., 1997). In 
addition, influenza virus also elicits strong CD4 and CD8 T cells responses in the 
lung(Doherty et al., 1997).  
 
2. Glycomics and immunity 
    
2.1 Glycosylation, glycomics, and glycosyltransferase 
Glycosylation refers to the generation of different types of glycans or sugars that 
are attached to proteins and lipids(Varki., 2009). Glycan biosynthesis occurs 
along the protein secretory pathway, predominantly, within the Golgi apparatus. 
There are also some other forms of glycosylation that occur in the cytoplasm and 
nucleus. There are two types of glycans, and their classification depends on the 
nature of their linkage. N-glycans are glycosidically linked to the asparagine 
residues of polypeptides; in contrast, O-glycans are linked to serine or threonine 




Glycomics refers to the comprehensive study of total glycan structures of a given 
cell or organism，and is referred to as the glycome(Varki., 2009). In parallel with 
proteomics, glycomics is becoming a major research field. In fact, the glycome is 
far more complicated than either the genome or proteome. Studies have showed 
that most proteins and lipids on the surface of cellular membranes, as well as 
those of pathogens, are modified with a dense array of glycans, which undergo 
variable and dynamic changes in the course of development and 
pathogenesis(Cobb and Kasper, 2005; Varki, 2006). Indeed, glycans serve as 
linking bridges between cell-cell and cell-extracellular matrix (ECM) and glycans 
are recognized by carbohydrate-binding proteins, such as lectins and adhesion 
molecules(Alavi and Axford, 2008; Ohtsubo and Marth, 2006). These interactions 
allow glycans to participate in virtually all cellular processes that impact health or 
disease. Specifically, glycans have been found to regulate protein folding, cell 
adhesion, signal transduction, molecular homeostasis, endocytosis, receptor 
activation, molecular trafficking, and self/nonself recognition(Ohtsubo and Marth, 
2006; Rudd et al., 2001; Varki., 2009).  
 
Glycan biosynthesis occurs in a serially ordered pattern that is primarily 
catalyzed by glycosyltransferases(Varki., 2009). Molecular cloning and 
sequencing analysis showed that glycosyltransferases are a large enzyme group, 
composing up to 2% of the genome. Different from the nucleotide polymerases 
that require template to initiate replication, glycosyltransferases elongate glycan 
chains independently of template. Glycosyltransferases orchestrate with other 
enzymes to partially compete for and add monosaccharides from donor substrate 
to acceptor substrates, yielded by previous enzymes(Varki., 2009). This occurs 
rapidly and sequentially, extending the linear and/or diverged sugar chain. 
Moreover, glycosyltransferases are expressed and regulated in a cell- and/or 
stage-specific manner.  As a consequence of this regulated expression, a given 
cell could readily and rapidly adopt a different glycan pattern on the cell surface 
in response to dynamic physiological or pathogenic stimuli. From this 
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perspective, abnormal changes in cellular processes caused by disease, are 
likely to generate a different glycan pattern on a given cell during disease 
processes(Ohtsubo and Marth, 2006; Varki., 2009). 
 
2.2 Glycosylation and disease 
2.2.1 Glycosylation and cancer 
Cancer is a class of progressive diseases where clones of a cell show 
uncontrolled growth(Hanahan and Weinberg, 2011). These clones may invade 
and destroy surrounding tissues, and sometimes metastasize, where the clones 
move to other sites in the body through blood or lymph circulation. The 
development of cancer, or carcinogenesis, is a multiple-stage process that 
includes cancer initiation, promotion, and progression. A wide range of altered 
molecular events is found to cause cancer, such as the disruption of cell cycle, 
and the dysregulation of intracellular and/or intercellular signaling(Duffy et al., 
2008; Hanahan and Weinberg, 2011).  
 
It has been reported decades ago that the glycosylation pattern changes in an in 
vitro mouse transformed fibroblasts(Meezan et al., 1969). Since then, with the 
application of more tools and approaches, a deep insight of the crucial roles of 
glycans at various stages of carcinogenesis has been gained from intense 
experimental investigations. For example, the survival of melanoma and sarcoma 
cells in vitro was hampered when treated with N-glycosylation inhibitors (Dricu et 
al., 1999; Girnita et al., 2000). This is because inhibition of N-glycosylation leads 
to the down-regulation of cell surface insulin like growth factor-1 receptor (IRG-
1R), which has been shown to be critical for tumor development(Dricu et al., 
1999). As a consequence, there is a drastic reduction of IRG-1R 
autophosphorylation. This case illustrates how altered glycosylation in surface 




Glycosylation also regulate other aspects of tumor progression. When tumor cells 
are ready to invade adjacent tissues, they detach themselves from each other 
and from the extracellular matrix (ECM) and then move to neighboring sites(Duffy 
et al., 2008). This occurs through the changes of expression of cell-surface 
adhesion receptors and ligands, and the secretion of proteolytic enzymes and 
glycosidases that break ECM networks. Tumor cells have been shown to 
increase the expression of N-acetylglucosaminyltransferase V (GnT V), which 
would upregulate the surface expression of complex β1,6-branched N-linked 
glycans(Dennis et al., 2002; Yoshimura et al., 1996). Particularly, increased 
modification of β1,6-branched N-linked glycan structure on the E-cadherin 
molecule expressing on tumor cell surfaces mediates cell aggregation via 
homotypic interactions(Dennis et al., 2002). This results in decreased cell-cell 
adhesions, promoting cell detachment and invasiveness(Dennis et al., 2002).  
 
2.2.2 Glycosylation and immune disorders 
Abnormal glycomodifications, which can be inherited or acquired, are found to 
correlate with a wide spectrum of diseases such as cancer as discussed above. 
Altered glycosylation has also been described in several immune disorders, 
including Wiskott-Aldrich syndrome (WAS), rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE), congenital disorders of glycosylation (CDG), 
leukocyte adhesion deficiency (LAD), and IgA nephropathy (IgAN)(Alavi and 
Axford, 2008; Ohtsubo and Marth, 2006).  Over the past decades, there is an 
increasing body of information regarding the mechanisms of glycan processing 
and their role in pathogenesis. 
 
2.2.2.1 Hereditary aberrant glycosylation associated immune diseases 
The numbers of diseases correlating with inherited aberrant glycosylation is 
relatively low due to either embryonic lethality mutations or limited tools to detect 
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mild syndromes(Alavi and Axford, 2008; Ohtsubo and Marth, 2006). Wiskott-
Aldrich syndrome is an X-linked inherited immunodeficiency disorder, caused by 
mutations in the Wiskott-Aldrich syndrome protein (WASP) gene(Notarangelo et 
al., 2005). The symptoms of WAS include peripheral lymphopenia, 
thrombocytopenia, small platelet, eczama, and recurrent infections(Imai et al., 
2004; Notarangelo et al., 2005). CD43 is a highly conserved transmembrane 
glycoprotein expressed on thymocytes and most hematopoietic cells(Notarangelo 
et al., 2005). CD43 has been shown to be involved in the regulation of T cell 
migration and immunity(Matsumoto et al., 2005; Onami et al., 2002). Aberrant 
glycomodifications of CD43 are present in WAS patients(Higgins et al., 1991; 
Piller et al., 1991). As altered glycoforms of CD43 have been shown to be 
important for T cell positive selection in the thymus, these changes might lead to 
abnormal thymic egress of self-reactive T cells, invoking autoimmune disease 
and progressive lymphopenia, which are commonly observed in WAS 
patients(Ellies et al., 1996; Khan et al., 2008).  
 
2.2.2.2 Acquired aberrant glycosylation associated immune diseases 
Extensive investigations have been carried out to illustrate the role of changes in 
the glycosylation of antibodies in autoimmune diseases(Opdenakker et al., 2006; 
Varki., 2009). A wealth of evidence suggested that the dysregulation of 
glycosylation in IgG contributes to the pathogenesis of the autoimmune disease 
rheumatoid arthritis (RA)(Alavi and Axford, 2008; Varki., 2009).  IgGs have 
various glycomodifications in the constant domain of Fc region, which can be 
terminally decorated by galactose, sialic acid, bi-antennary N-acetylglucosamine, 
and fucose(Jefferis, 2005; Kaneko et al., 2006). One key feature of RA is a 
significant increase in agalactosylated IgG, which is a good indicator of the 
severity of RA symptoms(Gindzienska-Sieskiewicz et al., 2007; Troelsen et al., 
2007). Without the galactosylation of IgG Fc region, it may alter immunogenic 
properties, resulting in auto-sensitization and the generation of anti IgG-G0 
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antibody, leading to the formation of immune complexes(Das et al., 2004; Varki., 
2009). Loss of terminal galactose in IgG Fc also expose mannoses, which 
normally are not accessible for mannose binding lectin recognition, and may 
trigger an inappropriately complement response, generating inflammatory factors 
that disturb normal cellular activities(Arnold et al., 2006). The abnormal 
glycosylation in IgG Fc also may affect the timing and specificity of interaction 
with Fc receptor, thus activating unwanted inflammatory responses that 
contribute to RA disease(Kaneko et al., 2006). 
 
2.2.2.3 IgA nephropathy 
IgA nephropathy (IgAN) is a common worldwide immune complex-mediated 
glomerulonephritis, characterized by IgA deposition in glomerular 
mesangium(D'Amico, 1987; D'Amico, 2004). It is often associated with IgG 
deposition, hematuria, sometimes with proteinuria, and usually associated with 
elevated IgA level in serum(D'Amico, 2004). 20-40% of IgAN patients will develop 
renal failure(D'Amico, 2004). Despite the significant morbidity and mortality 
caused by IgAN, the root cause of this disease remains unknown. Linkage 
studies could not convincingly establish any genes that correlate to IgAN(Gharavi 
et al., 2000; Paterson et al., 2007). Studies have shown that IgA1 was 
abnormally O-glycosylated in IgAN(Hiki et al., 1995; Mestecky et al., 1993). 
Immune complexes containing the abnormally O-glycosylated IgA1 and IgG or 
IgA1 autoantibodies against the aberrant IgA1 were also reported in IgAN 
patients(Novak et al., 2008). The dysregulated O-glycosylation of IgA1 in IgAN is 
now well established. However, the molecular mechanisms causing this 
dysregulation and the initiation of the disease process in IgAN remains largely 
unknown.  
 
Several groups have developed mouse models for human IgAN, including loss of 
uteroglobin, an anti-inflammatory protein, and a genetic knock-in mouse that 
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expresses human Fcα receptor on macrophages/monocytes(Launay et al., 2000; 
Zheng et al., 1999). Moreover, a recent study showed that β4GalT-1-deficient 
mice displayed most of the pathological and clinical traits of human IgAN, and 
therefore it may have utility as a novel animal model to study how aberrant 
glycosylation initiates an IgAN-lilke pathogenesis(Nishie et al., 2007). 
 
2.3 Sialyltransferase 
Sialic acids (SA) are a group of negatively charged 9-carbon monosaccharides 
derived from neuraminic acid. More than 50 naturally occurring SAs have been 
discovered(Varki and Varki, 2007). Numerous sialylated glycoconjugates have 
been identified, which exhibit remarkable diversity in both different linkages with 
other sugar molecules and structurally natural modifications in a cell type and 
developmentally modulated style(Varki., 2009). Typically, SAs are found 
abundantly attached to the outmost terminal positions of N-glycans, O-glycans 
and glycosphingolipids in all vertebrate cell types and throughout all tissues and 
body secretions. In addition, SA modifications often change in response to 
environmental signals. As a consequence of their tremendous diversity and 
terminal location on the cell membrane, SAs have been shown to play a wide 
variety of roles in many physiological or pathological processes, particularly in 
neural development, pathogen recognition, and immune function(Varki, 2008; 
Varki., 2009). 
 
As a subset of glycosyltransferases, sialyltransferases catalyze the transfer of 
sialic acid residues from donor substrate CMP-NeuAc to the terminus of 
glycoproteins and glycolipids within the reticulum-Golgi biosynthesis factory. To 
date, 20 different sialyltransferases have been identified to generate three key 
types of sialic acid linkage in mouse and humans. The most abundant sialic acid 
linkage is α2,3 linkage and is produced at least by 6 α2,3-sialyltransferases 
(ST3Gal I-VI). α2,8 sialic acid linkages are generated by 6 α2,8-
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sialyltransferases (ST8Gal I-VI). GalNAc α2,6-sialyltransferases (ST6Gal NAc-I-
VI) and α2,6-sialyltransferases (ST6Gal I and II) catalyze the addition of α2,6 
linked sialic acid to Galβ1,4GalNAc and Galβ1,4GlcNAc, respectively(Harduin-
Lepers et al., 1995; Takashima, 2008).  
 
2.3.1 α2,6-sialyltransferase family 
The Galβ1,4GlcNAc (lactosamine) is a common component at the end of N-
glycan chains of glycoproteins. It has been shown that ST6Gal I and II are the 
only two sialyltransferases to catalyze the addition of sialic acid to lactosamine to 
generate Siaα2-6Galβ1-4GlcNAc (Sia6LacNAc), a structure that is recognized by 
several lectins including a plant lectin Sambucas nigra agglutinin (SNA)(Hennet 
et al., 1998; Varki, 2008). ST6Gal II shows restricted acceptor substrate 
specificity toward oligosaccharides(Takashima, 2008). In addition, it is mainly 
expressed in brain and during embryonic development. In contrast, ST6Gal I 
exhibits broad substrate specificity toward glycoprotein, glycolipid, and 
oligosaccharides(Takashima, 2008). Moreover, ST6Gal I is expressed in many 
tissues at relatively low level except lymphoid organs(Takashima, 2008). Both 
ST6Gal genes have similar genomic structures. They use physically distinct 
promoters and the alternative splicing strategy to generate isoforms from primary 
RNA transcripts in different tissues(Wuensch et al., 2000). When P1, one of six 
promoters that drives murine ST6Gal I expression, is deleted, mice showed 
neutrophillia and eosinophillia, suggesting P1 region might be involved in the 
regulation of myelopoiesis(Nasirikenari et al., 2010; Nasirikenari et al., 2006). 
However, the functional relevance of these tissue-specific transcript variants is 




2.3.2 ST6Gal I and immune regulation 
ST6Gal I RNA is highly expressed in hematopoietic cells such as T and B cells, 
implicating a physiological role of ST6Gal I in hematopoietic cells(Kitagawa and 
Paulson, 1994; Wen et al., 1992). Indeed, ST6Gal I generates the Sia6LacNAc 
which serves as the ligand for the mammalian lectin CD22 molecule, which is 
exclusively expressed on B cells. CD22 is a transmembrane glycoprotein, which 
negatively regulates B cell signaling by recruiting phosphatase SHP-1 to the B 
cell receptor to dampen B cell signaling(Nitschke, 2005). When ST6Gal I 
knockout mice were generated, these mice displayed impaired B cell responses, 
including reduced serum IgM levels, hampered B cell proliferation in response to 
IgM and CD40 ligation, and impaired antibodies generation when immunized with 
T-independent (DNP-Ficoll) and T-dependent antigens (DNP-KLH)(Hennet et al., 
1998). These studies clearly showed that ST6Gal I played a critical role in B cell 
immune responses.  
 
Early studies reported that ST6Gal I-deficient T cells proliferated normally when  
stimulated with anti-CD3 antibody in vitro(Hennet et al., 1998). However, a global 
gene profiling analysis showed a significant decrease of Stgal1 mRNA after T cell 
activation(Comelli et al., 2006; Kaech et al., 2002), suggesting a role of ST6Gal I 
in T cell activation. Another study demonstrated that, compared to Th1 and Th17 
cells, Th2 CD4 T cells expressed significantly more ST6Gal I, which might 
account for reduced galectin-1 binding and subsequent apoptosis, implicating 
that ST6Gal I regulated CD4 T cell differentiation(Toscano et al., 2007). 
Nonetheless, the in vivo role of ST6Gal I in T lymphocyte immune responses 
remains largely unexplored. 
 
On the other hand, ST6Gal I is involved in inflammation regulation. It has been 
shown that knockout mice demonstrated significantly enhanced neutrophil and 
eosinophil infiltration into peritoneal cavity after intraperitoneally challenge with 
thioglycollate(Nasirikenari et al., 2010; Nasirikenari et al., 2006), suggesting a 
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regulatory role of ST6Gal I in inflammatory responses. Surprisingly, ST6Gal I 
also can contribute to modulating inflammation via differential α2,6-sialylation of 
IgG Fc fragment, which may determine the pro- or anti-inflammatory effects of 
IgG by regulating its binding to corresponding Fcγ receptors(Kaneko et al., 2006). 
 
2.3.3 ST6Gal I and disease 
It has long been appreciated that ST6Gal I expression correlated with 
inflammation(Dall'Olio, 2000). It seems that the expression of ST6Gal I, similar to 
acute phase proteins, is enhanced upon induced inflammation(Kaplan et al., 
1983). Furthermore, it has been suggested that IL-6 may regulate ST6Gal I 
expression, at least the induction of hepatic ST6Gal I (Dalziel et al., 1999). The 
increased expression of ST6Gal I during inflammation would generate higher 
levels of sialyl α2,6-lactosaminyl terminals, which might serve as decoy biding 
sites to prevent incoming pathogens from interacting with host cells that express 
surface α 2,6-linked sialic acid for important endogenous recognition. Another 
potential function of increased ST6Gal I is that the increased levels of α2,6 
sialylation would decrease the numbers of α2,3 sialylated epitopes, which are 
preferentially recognized by incoming pathogens(Gagneux and Varki, 1999). 
Thus, manipulating the expression of ST6Gal I might serve to combat pathogen. 
 
The increased expression of ST6Gal I has been implicated in diseases such as  
colon and breast carcinoma, acute myeloid leukemia, and in some brain tumors 
(Dall'Olio and Chiricolo, 2001). Moreover, increased Siaα2,6 Gal levels have 
been shown to enhance transformed cell motility and invasiveness in 
vitro(Chiricolo et al., 2006; Seales et al., 2005). A recent in vivo study 
demonstrated that loss of ST6Gal I affect the integrin signaling pathway, and 




3. B cell activation and differentiation 
  
3.1 B cell subsets and activation 
B cells undergo antigen-independent development first in bone marrow and then 
in spleen. After complete maturation, some B cells migrate to the marginal zone 
and remain there as naïve resident marginal zone (MZ) B cells(Steiniger et al., 
2006). The majority of B cells will go on to circulate to the splenic follicles, and to 
other sites, such as the lymph nodes and bone marrow(LeBien and Tedder, 
2008). After exposure to cognate antigen, B cells increase in size and start to 
proliferate to become B-cell blasts. Those B-cell blasts that synthesize and 
secrete antibody are named plasmablasts, and can terminally differentiate into 
plasma cells, which secret measurable amounts of immunoglobulin without 
proliferation. MZ B cells are unique in their inborn ability to rapidly (within hours) 
develop into short-lived plasma cells that secrete immunoglobulin, responding to 
antigenic stimuli in the absence of T-cell help(Oliver et al., 1997; Snapper et al., 
1993). In contrast, circulating naïve B cells require two signals to become fully 
activated and undergo further differentiation(Bonilla and Oettgen, 2010; Oracki et 
al., 2010). The first signal is the antigen-mediated cross-linking of the 
immunoglobulin receptor, which activates the intracellular signaling pathway. As 
a consequence of this activation, B cells internalize the antigen-BCR complex 
and process the antigen to peptides that subsequently conjugates to appropriate 
MHC II molecules. These peptide-MHC II complexes then are delivered to the 
cell surface. When B cells interact with previously activated CD4 T cells specific 
for this peptide-MHC II complex, the CD4 T cells provide direct cell-cell contact 
(signal 2) to fully activate B cells. Consequently, the activated B cells can 
undergo proliferation and differentiation to plasma cells to elicit extra-follicular 
responses. Alternatively, fully activated B cells enter germinal centers. Germinal 
centers are special sites within the follicle, where B cells change from the 
generation of IgM and IgD to other isotypes, such as IgA, IgG, and IgE through 
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rearrangement of gene segments that encode the constant region of 
immunoglobulin heavy chain(Stavnezer et al., 2008). Meanwhile, B cells also 
undergo rounds of proliferation to accumulate point mutations in the variable 
chains of the immunoglobulin heavy and light chain, a process called somatic 
hypermutation, which results in the production of antigen-specific 
immunoglobulins with high affinity(Peled et al., 2008). B cells eventually develop 
into long-lived plasma cells (LLPCs), or memory B cells (MBCs) expressing high-
affinity, and class-switched surface immunoglobulin receptors. These cells exit 
the germinal center approximately two weeks after immunization(Bonilla and 
Oettgen, 2010; Shapiro-Shelef and Calame, 2005). 
 
3.2 B cell memory 
B cell memory consists of two cellular components, including MBCs and 
LLPCs(Kurosaki et al., 2010; LeBien and Tedder, 2008). Both cell types provide 
long-term immunity. Generated in the germinal center, MBCs retain high affinity 
surface BCR and co-express the mature B cell markers B220 and 
CD19(Kurosaki et al., 2010). After exit from the germinal center, MBCs distribute 
throughout the body. MBCs can persist in the absence of antigenic stimulation 
and do not secrete immunoglobulin(Kurosaki et al., 2010). However, MBCs can 
more rapidly differentiate into plasma cells and produce antigen-specific antibody 
to contain an infection compared to naïve B cells when re-encounter the 
pathogenic agent and in the presence of CD4 T cell help. In contrast, LLPCs are 
terminally differentiated B cells with a long lifespan that constantly secrete high 
affinity antibodies and persist in the absence of antigen or additional 
proliferation(Bonilla and Oettgen, 2010). Once developed from intrafollicular B 
cells in the germinal center, LLPCs express the homing chemokine receptors 
CXCR3, CXCR6, and integrin α4β1, enabling LLPCs to migrate to bone marrow, 




4. CD8 T cell activation and differentiation 
 
4.1 Effector and memory CD8 T cell subsets are heterogeneous 
Antigen-inexperienced, naïve CD8 T cells egress from thymus and populate 
secondary lymphoid organs. During an infection, naïve CD8 T cells that interact 
with specific peptide-MHC I complex, costimulatory signals, and cytokines, 
become activated and undergo proliferation and differentiation into effector CD8 
T cells(Lefrancois and Obar, 2010; Smith-Garvin et al., 2009). During 
differentiation, they acquire effector cytotoxic activities, changes in adhesion 
molecules and chemokine receptor expression, which allows them to migrate to 
sites of infection. About one week following acute infection, antigen-specific CD8 
T cell numbers peak, then undergo a significant attrition or contraction, where 
only 5-10% of the cells survive and become long-lasting memory cells. Memory 
CD8 T cells are long-lived, maintaining stable numbers via homeostatic turnover 
that is IL-15 dependent. Memory CD8 T cells  remain in a resting state with low 
cytotoxicity, however, they are able to rapidly expand and regain effector 
functions following re-exposure to the same pathogen(Cui and Kaech, 2010; 
Lefrancois and Obar, 2010; Rutishauser and Kaech, 2010).  
 
Only a small number of effector cells survive to become memory cells. However, 
the phenotypic and transcriptional traits embedded in the effector cells, which 
direct them to differentiate either into end-stage effector cells, or into memory 
cells, are largely unknown. Recent work to compare the global gene expression 
profiles of naïve, effector, and memory cells identified a few genes that are 
distinctly expressed at different stages of CD8 T cells development(Kaech et al., 
2002; Schluns et al., 2000). First, IL-7Rα expression was identified as being 
differently expressed in effector subsets(Kaech et al., 2002). Together with the 
identification of surface marker killer cell lectin-like receptor G1 (KLRG1), which 
also distinguished effector populations, a new classification emerged where 
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effector subsets could be identified and used to study heterogeneity within 
effector CD8 T cells(Joshi et al., 2007; Sarkar et al., 2008). It is now established 
in several mouse infection models that during a primary infection, naïve CD8 T 
cells expand and differentiate into two subsets of effector cells, one termed short-
lived effector cells or SLECs (KLRG1hi IL-7Rαlo), also known as terminal 
effectors, and these cells account for the majority of effector cells. SLECs have a 
shortened lifespan, proliferate earlier and more extensively, and fade after 
pathogen clearance. The other subset is called memory precursor effector cells 
or MPECs (KLRG1lo IL-7Rαhi), and have higher capacity to give rise to memory 
cells(Joshi et al., 2007; Kaech et al., 2003).  
 
The memory CD8 T cell population is also heterogeneous. Memory CD8 T cells 
that show high expression of CD62L and CCR7 are defined as central memory 
cells (Tcm)(Cui and Kaech, 2010). These cells are preferentially localized in 
lymphoid organs, display low cytotoxic activity ex vivo, and have a higher 
capacity to proliferate and generate IL-2(Cui and Kaech, 2010; Rutishauser and 
Kaech, 2010). The other memory CD8 T cell subpopulation is termed effector 
memory CD8 T cells (Tem). These Tem, preferentially reside in non-lymphoid 
organs, maintain ex vivo lytic activity, undergo less homeostatic renewal, have a 
more limited lifespan, and lack expression of lymph node homing molecules such 
as CD62L and CCR7 (Hikono et al., 2007; Wherry et al., 2003).  
 
4.2 Regulation of CD8 T cell differentiation 
How do different populations of effector and memory CD8 T cells arise during a 
pathogen infection? A recent study demonstrated that the fate of naïve CD8 T 
cells is not predetermined: an individual naïve precursor CD8 T cell can develop 
into heterogeneous effector and memory CD8 T cell populations. In this study, 
single cell transfer of an antigen-specific naïve CD8 T cell into a recipient mouse, 
followed by challenge with Listeria monocytogenes, showed that different effector 
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and memory cell subsets could develop from a single precursor CD8 T cell. This 
study suggested the concept of “one naïve cell, multiple fate” regarding CD8 T 
cell development(Stemberger et al., 2007). But when and how the cell fate 
decision was made still remain controversial. Several models have been 
proposed to explain the developmental relationship of the effector and memory T 
cell, which differentially highlight the role of extrinsic factors, such as quality, 
duration, or quantity of antigenic stimulation, or the intrinsic factors in CD8 T cells 
themselves, such as the differentiation status(Chang et al., 2007; Kaech and 
Ahmed, 2001; Sarkar et al., 2008; Williams and Bevan, 2007).  
 
What determines the effector versus memory differentiation decision? It has been 
shown that many factors influence the establishment of heterogeneity of effector 
and memory CD8 T cell, such as the duration of infection, time of recruitment of 
naïve CD8 T cells during infection, sufficiency of inflammatory signals, and 
tissue-specific microenvironment(D'Souza and Hedrick, 2006; Hikono et al., 
2007; Joshi et al., 2007; Rutishauser and Kaech, 2010). These different signals 
may synergize with each other to drive T cell activation, proliferation, and 
differentiation(Harty and Badovinac, 2008; Mescher et al., 2006). It seems that 
activated CD8 T cells will automatically undergo an effector cell program, as both 
SLEC and MPEC possess lytic activity(Joshi et al., 2007). In particular, recently it 
has been reported that the strength of IL2-IL-2R signaling is strongly correlated 
with the cell fate of effector cells(Kalia et al., 2010; Obar et al., 2010; Pipkin et al., 
2010). In the presence of strong IL-2 signals or with a higher, early expression of 
IL-2 receptor α chain, cells rapidly acquire effector functions such as perforin and 
granzyme B expression, but show a reduced capacity to gain MPEC marker 
expression. On the other hand, with weak IL-2 inputs or low early expression of 
IL-2Rα, cells tend to undergo incomplete effector differentiation and obtain more 
features of memory cells(Kalia et al., 2010; Pipkin et al., 2010). These studies 
suggested that the dose of IL-2 signaling, or the ability to receive IL-2 input 
(surface expression level of IL-2Rα), might push early activated CD8 cells to 
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favorably differentiate towards terminal effector cell or memory cells. Other 
inflammatory cytokines, such as IL-12 and IFNα, also seem to augment SLEC 
development during pathogen infection(Joshi et al., 2007).  
 
As activated CD8 T cells are exposed to numerous signals during infection, how 
these exogenous signals are transmitted to cells and converted into 
transcriptional regulators that initiate and promote effector versus memory cell 
fate differentiation is a critical question. The gene expression levels of a range of 
transcription factors, such as Id2, Gfi-1, Blimp-1, and two highly homologous T-
box proteins T-bet and Eomesdermin, changes as the naïve CD8 T cell 
differentiates into effector cells. This suggests that transcriptional regulation plays 
an important role in CD8 T cell differentiation(Kaech et al., 2002; Rutishauser 
and Kaech, 2010). In particular, the expression of T-bet or Blimp-1 was found to 
be elevated in short-lived effector CD8 T cells relative to memory precursor 
cells(Joshi et al., 2007; Kallies et al., 2009; Rutishauser et al., 2009). In addition, 
T-bet or Blimp-1-deficient CD8 T cells preferentially developed into memory 
precursor cells, demonstrating their importance in the early steps of CD8 T cell 
differentiation. 
 
Within the cell, how exactly the downstream regulators of different exogenous 
signals cooperate to determine early CD8 T cells differentiation remains unclear. 
Different signals might take charge at different stages of development. The TCR 
signal is absolutely needed for the initiation of T cell activation and differentiation, 
although not necessarily memory differentiation as has been shown in several 
studies of lymphopenia induced memory(Cho et al., 2000; Hamilton et al., 2006; 
Lee et al., 2011). The extent of the activated CD8 T cell response is presumably 
enhanced by costimulatory signals(Smith-Garvin et al., 2009). To some extent, it 
seems that the combination of inflammatory cytokines, which probably represent 
certain cellular- or tissue- and/or stage- specific environment signals, tip the T 
cell developmental direction according to environmental cues. Downstream 
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transcriptional regulators that become activated following TCR signals might first 
open up and expose critical gene loci, which are targets for other downstream 
regulators of additional signals. Consequently, the expression level of specific 
transcription factors such as T-bet and other effector molecules might be 
altered(Letimier et al., 2007; Placek et al., 2009). Therefore, the activated CD8 T 
cells adopt either the terminal effector or SLEC differentiation or the MPEC 
program.  
 
5. Research focus 
The goal of my dissertation study was to extensively investigate the role of α2,6 
sialylation, catalyzed by the glycosyltransferase ST6Gal I in viral T and B cell 
immunity. I addressed several questions. What role does ST6Gal I expression 
play in antiviral humoral responses? How does ST6Gal I deficiency affect the 
generation of viral-specific antibody secreting plasma cells, long-lived plasma 
cells, and memory B cells?  What role does ST6Gal I expression by B cells play 
in the antiviral homoral response?  
 
Additionally, we examined how loss of α2,6 sialylation affected the generation of 
viral-specific IgA. How does sialylation of IgG and IgA change in the absence of 
ST6Gal I expression? Additionally, we examined the pathogenic outcome in 
ST6Gal I-deficient mice of IgA and IgG deposition in the kidney.  
 
Finally, we probed the role of ST6Gal I in virus-specific CD8 T cell responses. 
What is the relevance of the differential expression of ST6Gal I in CD8 T cell 
subpopulations following viral infection? How does loss of ST6Gal I affect the 
differentiation of effector CD8 T cells during acute viral infection? We determined 
the mechanisms underlaying differences in CD8 T cell differentiation in the 
absence of ST6Gal I. our studies revealed a role for ST6Gal I expression in 
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In this chapter, “our” and “we” refer to me and co-authors.  My contribution to this 
paper includes: 1) planning and performing experiments, 2) analyzing data, 3) 




Post-translational modification of proteins, such as glycosylation, can impact cell 
signaling and function. ST6Gal I, a glycosyltransferase expressed by B cells, 
catalyzes the addition of α-2, 6 sialic acid to galactose (Siaα2-6Gal), a 
modification found on N-linked glycoproteins such as CD22, a negative regulator 
of B cell activation. We show that SNA lectin, which binds Siaα2-6Gal, shows 
high binding on plasma blasts and germinal center B cells following viral 
infection, suggesting ST6Gal I expression remains high on activated B cells in 
vivo. To understand the relevance of this modification on the antiviral B cell 
immune response, we infected ST6Gal I-/- mice with influenza A/HKx31. We 
demonstrate that the loss of ST6Gal I expression results in similar influenza 
infectivity in the lung, but significantly reduced early influenza-specific IgM and 
IgG levels in the serum, as well as significantly reduced numbers of early viral 
specific antibody-secreting cells (ASCs). At later memory time points, ST6Gal I-/- 
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mice show comparable numbers of IgG influenza-specific memory B cells and 
long-lived plasma cells, with similarly high antiviral IgG titers, with the exception 
of IgG2c. Finally, we adoptively transfer purified B cells from WT or ST6Gal I-/- 
mice into B cell deficient (µMT-/-) mice. Recipient mice that received ST6Gal I-/- B 
cells demonstrated reduced influenza-specific IgM levels, but similar levels of 
influenza-specific IgG, compared to mice that received WT B cells. These data 





Humoral immunity is characterized by prolonged antibody production, even after 
resolution of infection, in stark contrast to the T cell response, where effector T 
cell function is relatively short-lived. Antibodies, by neutralizing or opsonizing free 
extracellular pathogens, serve as a critical first-line defense against infection.  
Humoral immunity is comprised of pre-existing antibody produced by antibody 
secreting cells (ASCs) termed long-lived plasma cells (LLPCs), as well as a 
population of memory B cells (MBCs) that can differentiate following antigenic 
stimulation into plasma cells (Kalia et al., 2006; Slifka and Ahmed, 1996; Slifka 
and Ahmed, 1998; Slifka et al., 1998).  
 
The enzyme ST6Gal I is a glycosyltransferase highly expressed by B and T cells 
that synthesizes the glycan sequence α2,6 sialic acid linked to galactose (Siaα2-
6Gal) (Hennet et al., 1998). This structure is typically found on N-linked glycans 
of glycoproteins, such as the mammalian lectin CD22, a transmembrane 
glycoprotein expressed by B cells that has high specificity for (Siaα2-6Gal). 
CD22 has been shown to be a negative regulator of B cell signaling by recruiting 
SHP-1 to the BCR, thus attenuating signals via the BCR (Collins et al., 2006; 
Hennet et al., 1998; Nitschke, 2005). The plant lectin Sambucas nigra agglutinin 
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(SNA) binds the product of ST6Gal I, Siaα2-6Gal, so SNA lectin binding can be 
used as an indicator of ST6Gal I expression and/or activity (Hennet et al., 1998). 
 
ST6Gal I null mice were initially described several years ago (Hennet et al., 
1998). These mice demonstrate normal T cell activation to anti-CD3 cross-linking 
in vitro, but defective BCR signaling in vitro, and reduced antibody production 
following immunization with T-independent and T-dependent antigens (DNP-
Ficoll or DNP-KLH) in vivo (Hennet et al., 1998). However, despite indications 
that B cell immune function may be compromised in these mice, as well as 
evidence that addition of cytokines could abrogate in vitro B cell proliferation 
differences, no studies have documented whether or not protective antibody and 
memory B cell responses are compromised in these mice when exposed to 
pathogenic microorganisms such as live viral infection.  
 
In this study, we have compared the outcome of influenza viral infection of wild 
type or ST6Gal I deficient mice. The haemagglutinin (HA) glycoprotein plays a 
key role in influenza pathogenicity and is involved in host-cell recognition 
(Horimoto and Kawaoka, 2005). First, we show that effective replication of 
influenza A/HKx31 (Orthomyxoviridae, Influenza A) does occur in the lungs of 
ST6Gal I-/- mice, however these mice demonstrate defective early influenza-
specific B cell responses. Next, we determine that expansion of CD4 and CD8 
influenza-specific T cell numbers in the lung and lymph nodes is normal in 
ST6Gal I-/- mice. Further, we demonstrate similar overall numbers of influenza 
specific IgG MBCs and LLPCs, though we note both a reduction in serum levels 
of influenza specific IgG2c and IgG2c producing LLPCs in the bone marrow. 
Finally, we demonstrate an impaired influenza specific IgM response in B cell 
deficient mice that receive ST6Gal I-/- B cells, suggesting that a B cell intrinsic 
defect partially contributes to the impaired humoral response.   Overall, our 
findings suggest that lack of ST6Gal I expression appears to prominently impair 
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the generation of a viral specific humoral response, but plays a lesser role in 
influenza-specific memory.  
 
Materials and methods 
 
Mice and immunizations 
ST6Gal I deficient mice were generated by J. Marth and obtained from the 
Consortium for Functional Glycomics and bred in-house (Hennet et al., 1998). 
C57BL/6 female mice and B6.129S2-Igh-6tm1Cgn/J (µMT-/- mice) were purchased 
from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained under 
specific pathogen-free conditions at the University of Tennessee in accordance 
with university IACUC guidelines and used at 6-12 weeks of age. Anesthetized 
mice were intra-nasally infected with 106.8 EID50 influenza A/HKx31 in 30 µl PBS 
as previously described (Li et al., 2006; Sangster et al., 2003). mMT-/- mice were 
primed with 107.4 EID50 influenza A/HKx31 i.p. 
 
Tissues harvest and flow cytometry 
At specified time points  (day 7, 10, > 40 post-infection), animals were sacrificed 
and tissues harvested for viral titer (lungs only), immunofluorescence, or isolation 
of lymphocytes. For isolation of lymphocytes from lungs, lungs were perfused 
with 5 ml cold PBS before removal and processed as previously described 
(Masopust et al., 2006). Single cell suspensions were stained with mAbs 
purchased from BD Pharmingen (CD4, CD8, CD44, B220, CD138, FAS, GL7, 
IFNg and TNFa), Vector Labs (SNA and PNA lectins), or Southern Biotech (IgD). 
Intracellular cytokine staining was assayed on cells from spleen, lung, and 
MedLN. All samples were run on a FACSCalibur (BD Biosciences). All data were 
analyzed with FlowJo software (Tree Star). Unpaired student t tests were 
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performed to determine statistical significance with *denoting p<.05 ** denoting 
P<0.01, and  *** denoting P<0.001. 
 
Immunofluorescence  
MedLNs were removed from mice on day 7 p.i. and frozen in OCT at –80oC. The 
frozen tissues were cut at 8-µm thickness, thaw-mounted onto slides, air dried 
and fixed in cold acetone for 10 minutes. The sections were then blocked with 
3% BSA and stained for germinal centers with PNA-FITC (Vector Laboratories), 
anti-B220-PE, and/or GL7-FITC (BD Pharmingen) as indicated. After staining, 
sections were washed with PBS, mounted using Vectashield mounting medium 
(Vector Laboratories), and analyzed using a laser scanning confocal microscope 
(Leica SP2). 
 
Influenza viral titer determination 
Lungs were collected on indicated days post-infection and homogenized in 
Hanks media with 0.1% BSA (GIBCO). Eight replicates of the homogenized lung 
were serially diluted tenfold across 96-well U-bottom plates in 1xMEM with 0.3% 
BSA, 1µg/ml Trypsin TPCK-treated (Worthington), penicillin (100IU/ml), 
streptomycin (100 µg/ml), and 5% FBS. The titrated lung samples were added to 
serum-free MEM MDCK cell monolayer prepared in 96-well tissue culture plates 
and incubated for 48h at 37°C and 5% CO2. Wells that were positive for viral 
growth were identified by testing supernatants for hemagglutinating activity using 
0.5% chicken red blood cells. 
 
ELISPOT assay to detect influenza specific ASCs 
A preparation of concentrated viral particles was disrupted for 10 min at room 
temperature in a 1:10 dilution of disruption buffer (0.5% Triton X-100, 0.6 M KCl, 
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and 0.05 M Tris-HCl, pH 7.5) in PBS, further diluted in PBS, and plated at 1 μ
g/well in nitrocellulose-bottomed 96-well Multiscreen HA filtration plates 
(Millipore, Bedford, MA). After overnight incubation at 4°C, plates were washed 
with PBS, and blocked with BCM containing 10% FBS. Plates were emptied by 
flicking, and cell suspensions (including resuspended cells from 96-well MBC 
assay plates) were added in volumes of approximately 100 μ l/well. After 
incubation for 3-4 h at 37°C in a humidified atmosphere containing 5% CO2, 
plates were thoroughly washed with PBS alone and PBS containing 0.1% Tween 
20. Alkaline phosphatase-conjugated goat anti-mouse IgG, IgM, or IgA (Southern 
Biotechnology, Birmingham, AL) diluted to 2 μg/ml in PBS containing 5% bovine 
serum albumin was added (100 μ l/well), and the plates were incubated 
overnight at 4°C. The plates were then washed extensively with PBS alone and 
PBS containing 0.1% Tween 20, including washing the underside of the 
nitrocellulose filters. Spots were developed at room temperature by the addition 
of 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma, St. Louis, MO) in 
diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM MgCl2, and 0.1 M 
Tris-HCl, pH 9.5), 100 μl/well. After spot development, plates were washed with 
PBS and dried, and spots representing individual ASCs were counted using an 
Olympus SZX9 stereozoom microscope. 
 
Memory B cell assay 
Influenza-specific MBC frequencies were determined by a previously described 
LDA based on in vitro stimulation of MBC to differentiate into ASCs (Joo et al., 
2008; Li et al., 2006). Briefly, two-fold dilutions of cells were incubated in 96-well 
tissue culture plates (routinely 12 wells per dilution), together with 106 irradiated 
(3000 rad) syngeneic naïve spleen cell feeders plus b-propiolactone-inactivated 
HKx31 (Charles River, Wilmington, MA). After incubation, cells in each well were 
transferred to ELISPOT plates for the enumeration of influenza-specific IgG 
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ASCs. Pre-existing virus-specific ASC numbers at the time of sampling were 
determined by direct ex vivo ELISPOT assay. After in vitro MBC activation and 
ELISPOT analysis, individual wells were scored positive for virus-specific MBC if 
progeny ASC numbers were greater than twice the mean pre-existing ASC. The 
virus-specific MBC frequency was calculated from the number of negative wells 
per cell dilution by extrapolation to the dilution that gave 37% negative wells (Joo 
et al., 2008). Linearity between the proportion of negative cultures and the input 
cell dose indicated direct measurement of MBC. No influenza-specific IgG ASCs 
were detected after in vitro stimulation of lymphocytes from naïve mice or from 
mice infected i.n 8 wk previously with an unrelated virus. 
 
B cell transfer and ELISA 
MACS B220 beads (Miltenyi Biotech) were used for purification of B cells 
according to the manufacturer’s instructions. Purity of B220+ B cells was 95% 
determined by FACS. 2x107 B220+ spleen cells were adoptively transferred into 
individual primed µMT deficient mice i.v. followed by infection with influenza i.n. 
24 hrs later. For serum antibody determination by ELISA, plates were coated with 
purified, detergent disrupted influenza A/HKx31 virus (0.5µg/well) and incubated 
at 4°C overnight. Plates were washed with PBS-Tween20 (0.05%), blocked with 
PBS/FBS (3%), and washed again. Serial three-fold serum dilutions were 
prepared in PBS-Tween20 (0.05%)-BSA (0.5%). The plates were incubated at 
RT 4 h or overnight at 4°C, then washed thoroughly. Plate-bound secreted Abs 
were detected using alkaline phosphatase-conjugated goat anti-mouse Abs with 
specificity for IgM, IgG, IgG1, IgG2b, IgG2c or IgG3 (Southern Biotechnology, 
Birmingham, AL) diluted in PBS-BSA (1%). After 4 h incubation at RT, plates 
were washed extensively, and color development with p-nitrophenyl phosphate 
(Sigma) in diethanolamine buffer was read at 405 nm using a Synergy2 Multi-
Detection Microplate Reader (BioTek Instruments, Inc.). The virus-specific serum 
Ab titer is expressed as the reciprocal of the highest dilution giving an 
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SNA binding is high on naïve and in vivo activated B cells 
The plant lectin SNA preferentially binds a2-6-linked sialic acids and previous 
reports have demonstrated high SNA binding on naïve lymphocytes that is 
abrogated in lymphocytes lacking ST6Gal I expression (Hennet et al., 1998). 
Gene expression studies comparing naïve B cells to in vitro activated B cells 
revealed that ST6Gal I expression remains high on activated B cells (Comelli et 
al., 2006). 
 
We examined SNA lectin binding by flow cytometry on B cells following in vivo B 
cell activation (Figure 2.1).  We observed that on day 8 following viral infection, 
B220+ CD138+ plasma blasts remain SNA high similar to B220+ IgD+ naïve B 
cells in uninfected mice. Additionally, on day 15 post-infection, B220+, Fas+, IgDlo 
germinal center B cells also show high SNA lectin binding (Figure 2.1).  
 
Impaired generation of influenza specific humoral responses in ST6Gal I 
deficient mice 
To examine the functional relevance of this modification for antiviral humoral 
responses, we obtained ST6Gal I null mice. ST6Gal I-/- mice develop normally 
and show a normal lymphoid compartment and architecture (Hennet et al., 1998; 
Martin et al., 2002).  However, B cells from ST6Gal I-/- mice show impaired 
proliferation in vitro to anti-IgM, anti-CD40, and LPS stimulation that can be 
rescued by the addition of IL-4, or gene ablation of CD22 (Collins et al., 2006; 
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Grewal et al., 2006; Hennet et al., 1998). These mice also show defective T-
dependent and T-independent humoral responses to hapten-protein 
immunization. Previous studies examining antibody responses following viral 
infection have sometimes contrasted with results using hapten-protein 
immunizations (Kawabe et al., 1994; Whitmire et al., 1999). We infected ST6Gal 
I-/- mice with influenza A/HKx31 and serially bled them to determine influenza-
specific IgM and IgG by serum ELISA (Figure 2.2A). We observed ~10-fold 
reductions and ~5-fold reductions in the levels of influenza-specific IgM and IgG, 
respectively on day 7 p.i.  (Figure 2.2A). Analysis of IgG isotypes on day 7 p.i. 
revealed that all isotypes were significantly reduced compared to wild type mice, 
with IgG3 and IgG2c showing the most impairment of the IgG isotypes (3- and 7-
fold, respectively) (Figure 2.2B). By day 14 p.i., influenza-specific IgG was similar 
comparing wild-type and ST6Gal I-/- mice, while influenza-specific IgM still 
remained impaired. 
 
One possible explanation for the differences observed could be aberrantly 
glycosylated antibodies are preferentially scavenged in vivo by lectin bearing 
macrophages (Onami et al., 2002). We determined whether ST6Gal I-/- mice are 
defective in the generation of viral specific plasma cells (Figure 2.2C). 
Examination of influenza-specific ASCs by ELISPOT in the CLN, MedLN, and 
spleen show significantly reduced numbers at day 7. Influenza-specific IgM 
producing ASCs showed the most impairment, especially in the spleen. 
Influenza-specific IgA producing ASCs were reduced, but the reduction was not 
statistically significant  (Figure 2.2C). These results show that the reduced serum 
levels of antiviral antibodies are likely not the effect of preferential scavenging by 





Germinal centers of ST6Gal I-/- mice do not bind GL7 
To determine if any differences in germinal center formation are present in 
ST6Gal I-/- mice, we performed immuno-staining in the lymph nodes. Our 
analysis of the MedLN by immuno-fluorescence on day 7 p.i. revealed that 
germinal center B cells in ST6Gal I-/- mice show no expression of the germinal 
center marker GL7, but show high binding by the PNA lectin (Figure 2.3A). These 
data are consistent with results demonstrating that the monoclonal antibody GL7 
shows specificity for a sialylated glycan epitope expressed on germinal center B 
cells (Naito et al., 2007).  FACS analysis of lymphocytes from the CLN of these 
mice gating on IgDloB220+ cells showed similar percentages and numbers of GC 
cells as measured by expression of germinal center markers Fas and PNA, and 
confirmed loss of GL7 binding (Figure 2.3B,D). We also noted that the MFI of 
PNA binding was significantly higher in ST6Gal I-/- GC cells compared to WT 
(MFI = 1178 vs 549). The frequencies of total plasma cells (CD138+B220+) were 
reduced in ST6Gal I-/- mice, consistent with the reduction in viral specific ASCs 
and as expected, showed no binding of the SNA lectin (Figure 2.2C and 2.3C). 
 
Productive infection and replication of influenza in ST6Gal I-/- mice 
Entry of influenza virus, as well as the productive infection and replication in lung 
epithelial cells is dependent on sialic acid modification of glycoproteins. 
Productive influenza infection in humans depends specifically on 
sialyloligosaccharides containing terminal N-acetyl sialic acid linked to galactose 
by an α2,6-linkage, while in mice the data suggests α2,3-linked sialic acids are 
important (Hatakeyama et al., 2005; Ibricevic et al., 2006). Influenza viral titers 
were determined in the lungs of mice infected with A/HKx31 (Figure 2.4). We 
confirm that similar to wild-type mice, lungs from ST6Gal I-/- mice become 
productively infected with influenza A/HKx31 and show comparable viral titers at 
day 3 and 5 p.i.  By day 7 p.i., we see a trend towards higher viral titers in the 
lungs of ST6Gal I-/- mice, which coincides with the early impairment of viral 
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specific antibody responses observed in these mice. However, this difference is 
not statistically significant (p=.07) and by day 10 virus was cleared by both wild-
type and ST6Gal I-/- mice. These results extend the findings in a recently 
published report showing several human influenza A viruses are able to 
productively infect the respiratory tract of mice lacking ST6Gal I expression 
(Glaser et al., 2007). 
 
Viral specific CD4 and CD8 T cells in the lungs and MedLN 
Since T cells also express ST6Gal I, we enumerated influenza-specific T cells 
isolated from the lungs or draining nodes (MedLN) of wild-type or ST6Gal I-/- mice 
on day 10 using CD4 specific (NP311-325) or CD8 specific (NP366-374) 
peptides performing intracellular cytokine staining to detect IFNg (Crowe et al., 
2006). ST6Gal I-/- mice generate similar numbers of viral specific CD4 and CD8 T 
cells in the lung and MedLN, show similar co-production of TNFa and IL-2, and 
show similar numbers of CD44high CD4 and CD8 T cells in these tissues (Figure 
2.5 and data not shown). However, we did note reduced numbers of viral specific 
CD8 T cells in the spleen on day 10 consistent with our observations of reduced 
viral specific T cells following LCMV infection in these mice.  
 
Viral specific memory B cell responses 
ST6Gal I-/- mice control influenza infection by day 10, despite impaired influenza 
specific humoral responses (Figure 2.4). The strong antiviral T cell responses in 
the lungs of these mice likely contribute to this effective viral clearance. Immune 
ST6Gal I-/- mice show high levels of class switched IgG antibody; however, a 
significant reduction in serum levels of IgG2c was observed, supported by a 
significant reduction in frequencies of influenza-specific IgG2c producing LLPCs 
in the bone marrow (Figure 2.6A,B). Examination of MBCs in the spleen and 
MedLN reveal comparable frequencies of total influenza-specific IgG MBCs 
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(Figure 2.6C). These results clearly indicate that with the exception of the 
reduced IgG2c levels, immune ST6Gal I-/- mice generated similar high titers of 
antiviral specific antibody. 
 
B cell expression of ST6Gal I is required to generate optimal levels of viral 
specific IgM 
Our data indicate that ST6Gal I-/- mice are able to generate strong antiviral 
humoral memory despite early impairments in the generation of the viral specific 
humoral response (Figures 2.2 and 2.6). To determine whether it is the 
expression of ST6Gal I by B cells alone that results in impairment of the early 
antiviral IgM and IgG response, we transferred purified naïve B cells from either 
wild-type or ST6Gal I-/- mice into primed B cell deficient µMT-/- mice. Recipient 
mice were intra-nasally infected with influenza, and serially bled to determine 
influenza specific antibody levels. Mice that received ST6Gal I-/- B cells show 
impaired influenza specific IgM levels, but similar viral specific IgG (Figure 2.7). 
These data argue that the observed impairment in production of viral specific IgM 
in ST6Gal I-/- mice is likely B cell intrinsic, however the impairment in early 
production of viral specific IgG is not B cell intrinsic. Thus, expression of ST6Gal I 
by B cells, at least in part, is required for normal antiviral humoral immunity. 
 
Discussion 
In this report, we have evaluated the influence of post-translational modification 
of glycoproteins on the immune response to influenza virus infection. Changes in 
the post-translational modification of glycoproteins during immune responses 
have been reported for decades, but their functional importance remains obscure 
(Baum et al., 1996; Galvan et al., 1998b; Harrington et al., 2000; Kosco et al., 
1988; London et al., 1978; London and Horton, 1980; Onami et al., 2002; 
Schrader et al., 1982). We demonstrate that in contrast to observations with PNA 
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lectin binding which changes during activation/differentiation B cells, naïve and 
activated B cells in vivo show similar high binding of SNA (Figure 2.1). This 
supports recently published data showing that ST6Gal I gene expression does 
not change following B cell activation in vitro (Comelli et al., 2006). Using ST6Gal 
I-/- mice, which lack the ability to catalyze the addition of α2,6 sialic acids to N-
linked glycoproteins, we investigated the role of this modification on the 
generation of an influenza-specific humoral response. Serum levels of influenza-
specific antibodies in these mice are reduced early in the immune response, with 
influenza-specific IgM responses showing the greatest impairment (Figure 2.2A). 
These data are supported by reductions in the frequencies of viral specific 
plasma cells, suggesting that the impaired viral specific antibody levels are likely 
a result of altered generation of short-lived viral specific plasma cells, and not a 
result of preferential scavenging of antibodies lacking α2,6 sialic acids. (Figure 
2.2C and 2.3C). Additionally, ST6Gal I-/- mice show no differences in influenza 
viral replication in the lungs, so the reduced antibody levels are not due to 
reduced viral load or antigen availability in these mice (Figure 2.4). We did 
observe comparable influenza-specific CD4 and CD8 T cell responses in the lung 
and draining lymph nodes of these mice, and this most likely explains why 
ST6Gal I-/- mice are able to control and clear influenza viral infection in the lungs 
by day 10, similar to wild-type mice (Figure 2.5). Despite significant impairments 
in the generation of an early antiviral humoral response, ST6Gal I-/- mice are able 
to generate potent antiviral humoral immunity, with high levels of class switched 
IgG antibodies by day 14 and memory time-points (Figure 2.2A, and Figure 2.6). 
This is the first reported analysis of antiviral immune responses in ST6Gal I-/- 
mice.  
 
To determine whether the observed impairment of antiviral humoral responses 
were B cell intrinsic, we adoptively transferred ST6Gal I+/+ or -/- B cells into primed 
B cell deficient µMT-/- mice (Figure 2.7). Primed mice were used to ensure 
adequate CD4 T help in these mice. The antiviral IgM response to infection was 
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substantially impaired in mice that received ST6Gal I-/- B cells. However, the 
antiviral IgG response was similar compared to mice that received wild-type B 
cells. These results suggest that the defective antiviral IgM response observed in 
ST6Gal I-/- mice is likely B cell intrinsic. While we must be cautious with our 
interpretations of antiviral responses in B cell deficient mice due to known 
alterations in lymphoid architecture, the results raise the possibility that subtle 
defects in an additional cell compartment in ST6Gal I-/- mice may contribute to 
the delayed antiviral IgG response. Future studies will investigate how ST6Gal I 
deficiency affects other lymphoid cells, and how this loss contributes to the 
defective anti-viral response. 
 
Recent reports have demonstrated that loss of expression of ST6Gal I by B cells 
results in preferential co-localization of the BCR with CD22, a negative regulator 
of BCR signaling, in clathrin-rich membrane microdomains (Collins et al., 2006; 
Grewal et al., 2006). Aged CD22 deficient mice have been reported to develop 
IgM autoantibodies (Walker and Smith, 2008). Ablation of CD22 expression in 
ST6Gal I-/- mice rescues BCR signaling defects (Collins et al., 2006). In naïve B 
cells, modification of CD22 by ST6Gal I normally results in segregation of CD22 
molecules, due to homotypic interactions with the α2, 6 sialic acid cis-ligands of 
other CD22 molecules (Collins et al., 2006). Following antigen receptor 
engagement, CD22 is tyrosine phosphorylated, and phosphorylated CD22 
recruits SHP-1 (Src homology domain2-containing tyrosine phosphatase), 
mediating signal inhibition via the BCR (Horikawa et al., 2007; Walker and Smith, 
2008). Due to the absence of these cis-CD22 ligands in ST6Gal I-/- mice, there is 
increased association of sIgM with the inhibitory receptor CD22 on naïve B cells; 
following antigen receptor engagement in vivo, this could result in immediate 
attenuated BCR signaling. We speculate that a possible in vivo outcome of this 
could be significantly impaired differentiation of naïve B cells into extra-follicular 
short-lived plasma cells following viral infection of ST6Gal I-/- mice (Benson et al., 
2007; Fujimoto and Sato, 2007; Junt et al., 2007; Paus et al., 2006; Walker and 
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Smith, 2008). Viral-specific B cells in the ST6Gal I-/- mice, with “weak or 
moderate BCR” signaling could enter germinal centers and undergo affinity 
maturation and differentiation into plasma cells. This could explain why we 
observe that after day 14 p.i, influenza-specific IgG responses are quite 
comparable to wild-type mice. Thus in a normal immune response, ST6Gal I 
modification of glycoproteins on naïve B cells may influence the signaling 
threshold required following antigen receptor signaling, and the biological 
outcome in vivo would favor differentiation of a greater proportion of Ag-specific 
B cells into extra-follicular short-lived plasma cells, important in the early control 
of pathogens. Alternatively, the repertoire of B cells available in ST6Gal I-/- mice 
could be different from wild-type mice due to differences in signaling strength 
during development (Ghosh et al., 2006; Santos et al., 2008). 
 
In conclusion, our data demonstrate that despite early defects in the generation 
of an antiviral humoral response, ST6Gal I-/- mice are able to clear virus and 
generate potent humoral memory. Further, our data suggests that loss of ST6Gal 
I expression by B cells may be responsible for the impaired antiviral IgM 
response. Finally, loss of expression of ST6Gal I in non-B cells likely contributes 
to the impaired IgG humoral response. Future experiments will elucidate how the 
expression of this enzyme by different lymphocyte populations, influences the 
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Figure 2.1. Binding of SNA on B cell populations.  
Splenocytes from uninfected C57BL/6 mice, or mice infected with 2x105 pfu 
LCMV Armstrong i.p. either 8 or 15 days earlier were used for the analysis. The 
left panel in B-D shows the gating, and the right panel SNA binding as 
histograms of the gated population. A, Cartoon depicting the glycosyltransferase 
ST6Gal I which catalyzes addition of terminal α2,6 sialic acids to galactose. SNA 
lectin binds Sia α 2-6Galβ1-4GlcNac. B, Naive B cells from uninfected mice 
gated on B220+/IgD+ cells C, CD138+/B220lo plasma blasts on day 8 and D, 











Figure 2.2. Influenza-specific B cell responses in ST6Gal I-/- mice during 
acute infection. 
B6 or ST6Gal I-/- mice were infected with influenza A/HKx31 i.n. and bled on 
indicated days. A, Serum virus-specific IgM (left), IgG (right) and B, IgG isotypes 
on day 7 were measured by ELISA. Data is expressed as the reciprocal endpoint 
antibody titer on serial titration of influenza antibody. C, Cell suspensions of CLN, 
MedLN and spleen were prepared from individual mice on day 7 p.i., and the 
ELISPOT  assay was used to measure the number of cells producing virus-
specific IgM, IgG1, IgG2b, IgG2c, IgG3 or IgA as indicated, with N =6-8 mice per 
group. Results are expressed as the number of ASC/105 nucleated cells. (∗, 



















Figure 2.3. Germinal center B cells of ST6Gal I-/- mice do not bind GL7. 
Mice were infected with influenza x31 i.n. and on day 7 p.i. lymph nodes were 
isolated and either frozen for immunofluorescence, or stained for FACS analysis 
using germinal center or plasma cell markers. Numbers show percentages of 
gated population. A, Immunofluorescence staining of MedLN using B220 and 
GL7 or B220 and PNA as indicated. B220 in red and GL7 or PNA staining in 
green. B, FACS analysis of germinal center B cells in CLN of same mice, gating 
on IgDloB220+ cells. Histogram shows GL7 binding on gated IgDloB220+ cells. 
Dot plot shows PNAhighFas+ cell population of gated IgDlowB220+ cells. C, FACS 
analysis of plasma cells in CLN gating on CD138+B220+ cells. Histogram overlay 
of SNA binding of gated population. Filled histogram shows ST6Gal I-/-, and open 
histogram shows B6. Bar graph shows frequencies of total plasma cells in 
indicated mice. D, Total number of germinal center B cells in CLN gating on 
IgDlowB220+ PNAhighFas+ or IgDlowB220+ GL7+ cells. Bar graphs show data from 








Figure 2.4. Influenza viral infection and clearance in lungs. 
B6 and ST6Gal I-/- mice were infected i.n. and on indicated days post infection, 
lungs were collected and assayed for influenza viral titer. Black/filled symbols are 
B6 mice and white/open symbols are ST6Gal I-/- mice. Each symbol represents 



















Figure 2.5. Influenza-specific T cell responses. 
At day 10 p.i., lymphocytes from MedLN and lung were stimulated with indicated 
peptides for 5 hrs, and stained for intracellular cytokine production of IFNγ. A, 
Representative staining for each tissue gating on CD4 or CD8 T cells. Numbers 
indicate the percentage of CD4 or CD8 T cells specific for each peptide. B, Total 
NP311-325 specific CD4 or NP366-374 CD8 T cells were enumerated in MedLN 





































Figure 2.6. Immune influenza-specific IgG responses. 
A, Influenza specific IgG isotypes from day 180 sera samples of B6 or ST6Gal I-/- 
mice. B, ELISPOT assay was used to determine the virus-specific IgG1, IgG2b, 
IgG2c and IgG3 antibody secreting cells in bone marrow of mice (LLPCs). C, 
Memory B cell numbers from spleen and MedLN; cells are pooled from 4 mice for 



























Figure 2.7. Loss of expression of ST6Gal I by B cells results in defective 
influenza specific IgM. 
A, Cartoon depicting experimental protocol where µMT-/- recipient mice were 
primed with 107.4 EID50 i.p; 90 days later, 2x107 purified naïve B220+ B cells from 
B6 or ST6Gal I-/- mice were adoptively transferred i.v. into mice. Control mice 
received no transferred cells. Mice were infected with 106.8 EID50 influenza 
A/HKx31 i.n. one day later and bled on indicated days. B, Serum virus-specific 








ST6GAL I DEFICIENCY RESULTS IN ALTERED SIALYLATION OF 
IGG AND IGA, AND PROMOTES IGA MESENGIAL DEPOSITION 








































ST6Gal I, a glycosyltransferase highly expressed by B cells, catalyzes the 
addition of α-2, 6 sialic acid to galactose (Siaα2-6Gal), a modification found on 
N-linked glycoproteins. Aberrant glycosylation has been associated with the 
pathogenesis of IgA nephropathy (IgAN), a disease characterized by immune 
complex deposits in the glomerular mesangium, which can lead to end-stage 
renal failure in 20-40% of diagnosed patients. We have previously shown that 
ST6Gal I-/- mice infected with influenza A/HKx31 demonstrated profound 
impairment in the generation of viral-specific humoral responses, although 
memory viral-specific IgG levels were normal.  
 
We have further analyzed influenza-specific humoral responses in ST6Gal I-/- 
mice. Here we report the paradoxical finding that at memory, influenza infected 
ST6Gal I-/- mice show higher influenza-specific IgA, as well as total IgA, 
compared to WT mice, despite impaired early responses. Using MALDI-TOF MS 
analysis and immuno-histology, we demonstrate that immune ST6Gal I-/- mice 
show significant deficiencies in N-glycan sialylation of IgG and IgA, as well as 
increased immunoglobulin deposition in the kidney glomeruli.  
 
These data show that loss of expression of an α-2,6 sialyltransferase, together 
with influenza viral infection, results in both aberrant glycosylation of IgG and IgA, 
and leads to increased immunoglobulin deposition in kidney glomeruli. These 
data raise the possibility that a common form of glomerulonephritis, IgAN, may 
be similarly initiated by altered sialyltransferase gene expression in concert with 








The enzyme ST6Gal I is a glycosyltransferase highly expressed by B and T cells 
that synthesizes the glycan sequence α2,6 sialic acid linked to galactose (Siaα2-
6Gal) (Hennet et al., 1998). This structure is typically found on N-linked glycans 
on glycoproteins such as the mammalian lectin CD22, a transmembrane 
glycoprotein expressed by B cells with high specificity for (Siaα2-6Gal). CD22 is 
a negative regulator of B cell signaling that recruits SHP-1 to the BCR, thus 
attenuating signals via the BCR (Collins et al., 2006; Hennet et al., 1998; 
Nitschke, 2005). Several studies of ST6Gal I null mice demonstrated that these 
mice show profound impairment in the generation of humoral responses to viral, 
protein, and hapten antigens (Hennet et al., 1998; Zeng et al., 2009). These 
defective humoral responses observed in ST6Gal I-/- mice are at least partially B 
cell intrinsic, and are likely due to impaired B cell responses due to altered co-
localization of the BCR with the negative regulator CD22 (Collins et al., 2006; 
Grewal et al., 2006; Zeng et al., 2009).  Despite defects in the early generation of 
humoral responses, ST6Gal I-/- mice control influenza viral infection and generate 
potent humoral memory (Zeng et al., 2009). 
 
Humoral immunity is characterized by prolonged antibody production, even after 
resolution of infection, in stark contrast to the T cell response, where effector T 
cell function is relatively short-lived. Antibodies, by neutralizing or opsonizing free 
extracellular pathogens, serve as a critical first-line defense against re-infection.  
Humoral immunity is provided by pre-existing antibody produced by a population 
of antibody secreting cells (ASCs) termed long-lived plasma cells (LLPCs), as 
well as a population of memory B cells (MBCs) that can rapidly differentiate 
following antigenic stimulation into plasma cells (Kalia et al., 2006; Slifka and 




Recently, work from several groups has demonstrated an important role for IgG 
terminal glycosylation. Terminal glycans influence binding to Fc receptors and 
C1q of complement, and sialylation has specifically been shown to have 
important effects on antibody function (Nimmerjahn and Ravetch, 2007; Raju, 
2008). Therapeutically, intravenous immune globulin (IVIG), which is used for the 
treatment of diverse autoimmune and systemic inflammatory diseases, has been 
shown in animal models to mediate enhanced anti-inflammatory effects when 
enriched for sialic acid containing IgG (Anthony et al., 2008; Kaneko et al., 2006; 
Kaveri et al., 2008). Thus alterations in sialylation of IgG may critically influence 
its function and clearance. 
 
In addition to a role for glycosylation in IgG function and human disease, aberrant 
glycosylation of IgA has also been implicated in human disease, specifically in 
the pathogenesis of IgA nephropathy (IgAN), one of the most common forms of 
glomerulonephritis globally (Allen and Feehally, 2000; Nishie et al., 2007; Raska 
et al., 2007; Suzuki et al., 2008; Tomana et al., 1999; Xu et al., 2005). Recent 
examination of IgAN patients suggested that expression of an α2,6 
sialyltransferase (ST6GALNAcII) is significantly reduced in peripheral B cells 
from patients suffering from IgAN, and IgAN patients show reduced IgA1 α2,6 
sialic acid content (Khan et al., 2008). IgA1 is the dominant circulating subclass 
of IgA in humans and primates, but not other species, and is characterized by a 
hinge region containing as many as 5 O-linked glycans (Glassock, 2009; Novak 
et al., 2008). Although murine IgA does not have the O-glycans characteristic of 
human IgA1, a recent study of mice lacking the β-1,4 galactosyltransferase I 
(β4GalT-I) reported the spontaneous development of a human IgAN-like disease, 
characterized by glomerular lesions, increased IgA levels, and IgA deposition in 
kidneys (Nishie et al., 2007). However, only a single infant patient has ever been 
diagnosed with a congenital mutation in β4GalT-I, so the relevance of this 
enzyme to IgAN disease development in humans remains obscure (Hansske et 
al., 2002). Recently, a study found an association between mutations in core 1 
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β1,3-galactosyltransferase I (C1β3GalTI) and genetic susceptibility to IgAN, 
suggesting that galactose-deficiency may play a role in disease development (Li 
et al., 2007a; Novak et al., 2008). This work fits with data suggesting that many 
IgAN patients exhibit under-galactosylation of O-glycans in the IgA1 hinge region, 
and that abnormal IgA1 glycosylation is a heritable trait (Gharavi et al., 2008).  
However, since many family members with abnormal IgA1 glycoforms remain 
asymptomatic, additional factors other than aberrant glycosylation appear to be 
required for IgAN disease development and pathogenesis (Gharavi et al., 2008). 
 
In the following report, we investigated the nature of alterations in terminal 
glycans in serum immunoglobulins from ST6Gal I-/- mice to determine whether 
ST6Gal I-/- mice developed any evidence of glomerulonephritis. We show that 
despite impaired generation of influenza-specific humoral responses, ST6Gal I-/- 
mice paradoxically showed higher levels of influenza-specific IgA and total IgA by 
day 60 p.i. We also show that although levels of influenza-specific IgG and total 
IgG were comparable in immune ST6Gal I-/- and WT mice, IgG N-glycans were 
characterized by a complete deficiency of terminal sialylation in ST6Gal I-/- mice. 
Moreover, while gross pathology of the mesangial matrix and kidney function 
remained normal, influenza immune ST6Gal I-/- mice show significant IgA and 
IgG deposition in the glomeruli. Examination of glycosylation differences for IgA 
also revealed that ST6Gal I-/- IgA showed aberrant terminal sialylation. Our data 
raise the possibility that a combination of influenza infection history, as well as 
genetic remodeling of protein glycosylation, such as loss of expression of an α2,6 








Materials and Methods 
 
Mice and immunizations 
ST6Gal I-deficient mice were originally generated by J. Marth (University of 
California, San Diego) and obtained from the Consortium for Functional 
Glycomics and bred in-house, backcrossed to C57BL/6 x10 generations (Hennet 
et al., 1998). C57BL/6 female mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Mice were maintained under specific pathogen-free 
conditions at the University of Tennessee in accordance with university IACUC 
guidelines. Anesthetized mice were intra-nasally infected with 106.8 EID50 
influenza A/HKx31 in 30 µl of PBS, as previously described (Zeng et al., 2009). 
 
Urinalysis 
Urine samples from C57BL/6 or ST6Gal I-/- mice were obtained at day 0 
(uninfected) or day 380 post-infection (p.i).  Chemstrip 5 OB urinalysis strips 
(Roche Diagnostics, Indianapolis, IN) were used to test urine samples for 
hematuria and proteinuria.  Urine samples were also tested for albumin content 
via a double-sandwich ELISA kit using affinity-purified goat anti-mouse albumin 
antibody and HRP-conjugated goat anti-mouse albumin antibody, as per the 
manufacturer’s instructions (Bethyl Laboratories, Montgomery, TX).   
 
Histological Analysis 
Kidneys were harvested from influenza immune mice, fixed in 10% formalin, 
embedded in paraffin and thin sections cut on a microtome.  Sections were 





Kidneys were harvested from mice at day 0 and day 400 p.i. and frozen in O.C.T. 
compound at -80°C.  Kidneys were sectioned at 7 µm, and frozen sections were 
blocked with 3% BSA in PBS, stained with IgG-biotin or IgA-biotin, followed by 
streptavidin-AlexaFluor 488.  Sections were examined using an epi-fluorescent 
microscope (Nikon Eclipse E600). The mean fluorescence was measured on the 
same samples using a Nikon NIS-Elements BR 2.30, measuring the MFI of three 
randomly selected glomeruli per sample. Unpaired student t tests were 
performed to determine statistical significance with *denoting p<.05 ** denoting 
P<0.01. 
 
Immunoglobulin Measurement by ELISA 
Total IgA or total IgG was measured in serum or vaginal washes of individual 
mice at day 0, day 7, day 14 or day 60-175 p.i. with influenza.  Plates were 
coated with goat anti-mouse IgA or goat anti-mouse IgG (Southern Biotech, 
Birmingham, AL) and incubated at 4°C overnight.  Plates were washed with PBS-
Tween 20 (0.05%), blocked with PBS-BSA (3%), and washed again.  Serial 3-
fold sample dilutions were prepared in PBS-Tween 20 (0.05%) and BSA (0.5%).  
The plates were incubated at room temperature for 4 h or overnight at 4°C then 
washed thoroughly.  Plate-bound secreted Abs were detected using alkaline 
phosphatase-conjugated goat anti-mouse Abs with specificity for IgA or IgG 
(Southern Biotech) diluted in PBS-BSA (1%) and incubated for 4 h at room 
temperature or overnight at 4°C.  Plates were then washed thoroughly, and color 
development with p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO) in 
diethanolamine buffer was read at 405 nm using a Synergy II Multi-Detection 
Microplate Reader (Bio-Tek Instruments, Winooski, VT).  The Ab titer is 
expressed as the reciprocal of the highest dilution giving an absorbance value 
more than twice that for simultaneously titrated samples from naïve mice.  
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Influenza-specific titers were measured as previously described (Sangster et al., 
2003; Zeng et al., 2009). 
 
IgG and IgA purification 
IgGs were purified from serum samples on a FPLC system by affinity 
chromatography at a flow rate of 1ml/min. Mouse serum (1 ml) was loaded on a 1 
ml protein A/G affinity column that had previously been equilibrated with 100 mM 
NaPO4, 150 mM NaCl, pH 7.2 (buffer A). The column was subsequently washed 
with 10 column volumes of buffer A. Bound IgGs were eluted with 0.1 M glycin 
pH 2.3. Fractions of 500 µL were collected in tubes containing 50-µL 
neutralization buffer (1M Tris, pH 8.8). Finally, all the fractions containing 
antibodies were pooled and concentrated using 30-kDa cut-off filter system. For 
IgA, mouse serum (400 µL) was applied to 600µL Jacalin-sepharose slurry 
previously equilibrated with buffer A. The mixture was incubated for 30 min at 
room temperature then the beads were washed extensively as follows: first 400 
µL, then 1500 µL buffer A, each with 15 min. incubation under rotation. IgAs were 
eluted from the slurry in 1.5 ml buffer A supplemented with 0.1 M α-D-galactose. 
 
N-glycan release 
IgG (50 µg) were digested with trypsin for 16 h at 37°C. The reaction was  
terminated by heating the sample for 5 min at 95°C. Antibodies were further 
digested with 100 mU PNGase F (EC 3.5.1.52; Roche Applied Science, IN) for 
18 h at 37°C. Released N-glycans were isolated and desalted on reverse-phase 
Sep-Pak C18 cartridges (Alltech, Deerfield, IL) followed by carbograph extract-




Sialidase digestion and Permethylation 
IgA samples, dissolved in 50mM phosphate buffer pH 6.0, were digested 
overnight at 37°C with 5 U/ml Streptococcus pneumoniae neuraminidase 
(sialidase S) (GKX-80020, Prozyme, San Leandro, CA). Permethylation was 
carried out using methyl iodide as described previously (von Horsten et al., 2010; 
Wedepohl et al., 2010). After the reaction, chloroform was added and the 
chloroform phase was washed with water until the pH of the water phase was 
neutral. The chloroform phase was finally evaporated under reduced atmosphere 




MALDI-TOF mass spectra were recorded on a Ultraflex III mass spectrometer 
(Bruker Daltonics) equipped with a Smartbeam laser and a LIFT-MS/MS facility. 
Spectra were recorded in reflector positive ionization mode. 0.5 µl desialylated or 
permethylated N-glycans were mixed on the ground steel target in a ratio 1:1 with 
the matrix consisting of D-arabinosazone (5 mg/ml) dissolved in 70% aqueous 
ethanol (Wedepohl et al., 2010). Calibration was performed on a glucose ladder. 
 
Results 
Increased IgA levels in influenza immune ST6Gal I-/- mice 
We have previously examined influenza-specific antibody responses in ST6Gal I-
/- mice and showed significant impairment in the generation of influenza-specific 
IgM and IgG responses (Zeng et al., 2009). However, memory B cell (MBC) and 
long-lived plasma cell (LLPC) responses were robust in immune ST6Gal I-/- mice 
(Zeng et al., 2009). In this study, we analyzed influenza-specific IgA responses. 
In naïve mice, there were no significant differences in total IgG or total IgA 
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comparing WT and ST6Gal I-/- mice (Figure 3.1A). However, we discovered that 
levels of total IgA, as well as influenza-specific IgA, were significantly higher in 
immune ST6Gal I-/- mice at day 175 (Figure 3.1A). To examine this difference in 
more detail, mice were infected with influenza A/HKx31 i.n. and mice were 
serially bled to obtain longitudinal samples from individual mice. While both 
influenza-specific IgG and influenza-specific IgA were significantly reduced at 
day 7 in ST6Gal I-/- mice, by day 15 IgG and IgA levels were similar, and by day 
60 (memory), influenza-specific IgA levels had surpassed levels in WT mice, in 
contrast to influenza-specific IgG, which remained comparable (Figure 3.1B). We 
also observed increased influenza-specific IgA levels in mucosal secretions of 
ST6Gal I-/- mice (data not shown). 
 
Since circulating IgA levels were higher in ST6Gal I-deficient mice, we examined 
whether these mice exhibited any defects in kidney function since high levels of 
serum IgA is a hallmark of IgAN. Urine samples were collected from immune 
mice and examined for the presence of blood (hematuria) or proteins 
(proteinuria) using urinalysis test strips (Table 3.1). We also measured urine 
albumin levels by ELISA (Figure 3.1C). ST6Gal I-/- mice were similar in all 
measures of kidney function to WT mice (Figure 3.1C and Table 3.1). 
Histological analysis of kidney sections from immune mice by H&E (Figure 3.1D) 
or PAS staining (not shown) revealed similarly normal gross pathology, with no 
evidence of mesangial proliferation in the glomeruli.  
 
 
ST6Gal I-/- mice show greater IgG deposition in glomeruli following 
influenza infection 
The first description of IgAN disease established that immunoglobulin deposition 
preceded development of pathological abnormalities in kidney (Berger and 
Hinglais, 1968). Since ST6Gal I-/- mice exhibited normal gross pathology of the 
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kidneys, we examined kidney glomeruli to determine whether there was evidence 
of immunoglobulin deposition. Frozen kidney sections from uninfected (naïve) 
WT and ST6Gal I-/- mice were first examined for IgG deposition in the glomeruli 
by immuno-fluorescence. No significant deposition was observed in either naïve 
WT or naïve ST6Gal I-/- mice (Figure 3.2A, upper panels). However, both WT and 
ST6Gal I-/- influenza immune mice showed significant IgG deposition in the 
glomeruli compared to naïve mice (Figure 3.2A, lower panels), consistent with 
several studies that have previously established that immunization or infection 
results in increased immune complex deposition in the kidney that is easily 
detected by immuno-fluorescence (Dixon et al., 1961; Semkow and Wilczynski, 
1979a; Semkow and Wilczynski, 1979b).  To ascertain if there were any 
differences in IgG deposition comparing immune WT versus immune ST6Gal I-/- 
mice, we measured mean fluorescence intensity (MFI) of IgG in the kidney 
glomeruli (Figure 3.2B). This additional analysis revealed that ST6Gal I-/- immune 
mice showed a consistent trend of greater IgG deposition (~30%) compared to 
WT immune mice (p<0.05).  Taken together, these data show that following 
influenza infection, WT and ST6Gal I-/- mice show significant IgG deposition in 
the kidney glomeruli, however ST6Gal I deficiency leads to higher IgG 
deposition. 
 
ST6Gal I expression is required for sialylation of N-glycans on IgG 
Since IgG levels were similar in all groups of mice, but IgG deposition varied 
(Figure 3.1A, 3.2B), we hypothesized that changes in the quality of IgG were 
contributing to differences in IgG deposition in the kidney glomeruli. Following 
influenza infection of mice, there is a significant increase in influenza specific-IgG 
titers (Figure 3.1B), resulting in the formation of antigen-antibody immune 
complexes that deposit in kidneys (Figure 3.2 and (Semkow and Wilczynski, 
1979b)). However, it has also been known for many years that significant 
changes occur in glycosylation during an immune response, with substantial 
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changes in lectin binding such as peanut agglutinin (PNA) binding by B and T cell 
glycoproteins and glycolipids (Galvan et al., 1998b; Kersh et al., 2003; London et 
al., 1978; Onami et al., 2002; Schrader et al., 1982). Aberrant immunogobulin 
glycosylation has been proposed to influence the pathogenesis of 
glomerulonephritis by influencing clearance mechanisms of immune complexes 
from the circulation (Novak et al., 2008). 
 
We examined alterations in IgG N-glycans by performing MALDI-TOF analysis of 
purified IgG from sera samples from naïve and immune WT, as well as naïve and 
immune ST6Gal I-/- mice. N-glycans were released and isolated from IgG 
samples, and they were subsequently permethylated for mass spectrometric 
analyses by MALDI-TOF-MS. When we compared N-glycans of IgG for naïve 
versus influenza immune WT mice, we observed no significant changes (Figure 
3). Similarly, no differences were observed comparing naïve and immune 
ST6Gal I-/- IgG (Figure 3.3). These data confirm that overall, composition of IgG 
N-glycans remains similar before and after influenza infection. Importantly, our 
analysis revealed that sialylated N-glycans of IgG, which were present in WT 
mice, were completely absent in ST6Gal I-/- IgG (Figure 3.3, right panels). This 
deficiency of sialylated N-glycans was seen with IgG purified from both naïve and 
immune ST6Gal I-/- mice (Figure 3.3). In the IgG fraction from WT mice, mono- 
and di-sialylated N-glycans could be found in both naive and influenza immune 
samples at m/z 2431.2, 2635.4 and 3026.6. This observation suggests that 
Neu5Gc in IgG N-glycans are exclusively (α-2,6)-linked. These results provide 
evidence that ST6Gal I expression is required for the synthesis of sialylated N-
glycans on mouse IgG.  
 
Loss of ST6Gal I expression leads to aberrant IgA glycosylation 
Since our analysis of IgG N-glycans revealed significant changes in sialylation, 
we asked whether similar changes occurred in IgA. We therefore performed 
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MALDI-TOF analysis of N-glycan structures from purified IgA obtained from 
serum samples from WT and ST6Gal I-/- mice to examine changes in N-glycan 
sialylation of IgA. Previous reports have established that N-glycans of IgA are 
sialylated bi-and tri-antennary complex-type glycans (Lipniunas et al., 1993). 
These sialylated N-glycans are acidic and generally give poor MALDI mass 
spectra (Harvey, 1999; Nishie et al., 2007). We therefore examined mass spectra 
of IgA N-glycans before and after digestion with an α2,3 sialidase.  
 
N-glycans were released and isolated from IgA and were subsequently 
permethylated for mass spectrometric analyses by MALDI-TOF-MS. A fraction of 
the IgA samples was digested with sialidase S before being permethylated. As 
shown in Figure 3.4A, before treatment with sialidase, IgA samples contained 
sialylated N-glycans and no differences were noted comparing WT and ST6Gal I-
/- IgA. However, following sialidase treatment clear differences were noted 
between WT and ST6Gal I-/- IgA (Figure 3.4B). Comparing purified IgA from WT 
versus ST6Gal I-/- mice, we discovered that α2,3 sialidase abolished virtually all 
sialylated N-glycans in ST6Gal I-/- IgA (Figure 3.4B).  In contrast, sialylated N-
glycans remained prominently visible on IgA from WT samples treated with α2,3 
sialidase (Figure 3.4B). Similar results were obtained using IgA from naïve WT 
mice compared to naïve ST6Gal I-/- mice (data not shown). These data 
demonstrate that mouse IgA contains both α2,3- and α2,6-linked sialic acids on 
N-glycans, in contrast to mouse IgG where loss of expression of ST6Gal I 
revealed that sialic acids on N-glycans were exclusively α2,6-linked (Figure 3.3). 
Moreover, these data illustrate that loss of expression of ST6Gal I results in 




Loss of ST6Gal I expression and influenza infection results in mesangial 
IgA deposition 
Finally, since our data indicated immune ST6Gal I-/- mice had high circulating 
levels of aberrantly glycosylated IgA, we examined kidney glomeruli of WT and 
ST6Gal I-/- mice by immuno-fluorescence to determine whether they showed IgA 
deposition. Naive WT mice show little evidence of IgA deposition in the glomeruli, 
and this was also true for naïve ST6Gal I-/- mice (Figure 3.5A, upper panels).  
Immune WT mice also showed little evidence of IgA deposition. In contrast, 
immune ST6Gal I-/- mice showed significant mesangial IgA deposition (Figure 
3.5A, lower panels). Measurement of IgA mean fluorescence confirmed our 
observation of significantly higher deposition (Figure 3.5B). In contrast to IgG 
deposition, where we observed that influenza infection of both WT and ST6Gal I-/- 
mice resulted in IgG deposits in the kidney glomeruli, IgA deposition was only 
evident in immune ST6Gal I-/- mice (Figure 3.2 and 3.5). Thus, IgA deposition 
appeared to be influenced both by 1) immune history and 2) genetic remodeling 
of protein glycosylation. Perhaps, altered sialylation of N-glycans causes a 
conversion to occur, transforming normal IgA into pathogenic IgA, resulting in IgA 
mesangial deposition in ST6Gal I-/- influenza immune mice.  
 
Discussion 
Glycosylation is an important post-translational modification that influences 
several aspects of protein function, including conformation, stability, activation, 
and clearance from the circulation. Aberrant glycosylation has been implicated in 
several human diseases including cancer and metastasis, leukocyte adhesion 
deficiency diseases (LAD/CDG-IIc), and muscular dystrophy (Freeze and 
Schachter, 2009; Varki., 2009). Understanding how changes in glycosylation 




We have previously reported that mice deficient in ST6Gal I-/- show altered 
immune responses, including significant impairments in the generation of 
humoral responses (Hennet et al., 1998; Zeng et al., 2009). In this report, we 
make the paradoxical observation that although generation of influenza-specific 
IgA responses are also impaired in ST6Gal I-/- mice, by memory time-points 
immune ST6Gal I-/- mice display increased levels of circulating viral-specific and 
total IgA (Figure 3.1). Our observation of increased IgA levels in immune ST6Gal 
I-/- mice led us to examine whether these mice developed evidence of 
glomerulonephritis. 
 
Analysis of immune ST6Gal I-/- mice revealed that although these mice show 
evidence of normal kidney function (Figure 3.1 and Table 3.1), they also show 
increased IgG and IgA deposition in kidney glomeruli (Figure 3.2 and Figure 3.5). 
Glycan analysis of IgG and IgA by MALDI-TOF revealed that N-glycans of both 
IgG and IgA from ST6Gal I-/- mice show aberrant glycosylation (Figure 3.3 and 
Figure 3.4). These alterations in glycosylation were characterized by significant 
losses in sialylation as evidenced by a complete deficiency of terminally 
sialylated N-glycan structures in IgG, and reductions in sialylated N-glycans in 
IgA (Figure 3.3 and 3.4). Together, these data suggest that expression of this 
α2,6 sialyltransferase is critical for the synthesis of terminal sialic acids on IgG 
and IgA, and may influence circulating antibody levels and immunoglobulin 
deposition in the kidney glomeruli. 
 
The sialic acid content of antibodies has been proposed to play a key role in the 
anti-inflammatory therapeutic effect of IVIG via Fc interactions with activating and 
inhibitory FcγRs (Nimmerjahn and Ravetch, 2007). Although it plays a primary 
role in protective humoral immunity, IgG also plays a pathogenic role in 
autoimmune diseases via the generation of auto-antibodies such as occurs in 
systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), 
rheumatoid arthritis (RA), and multiple sclerosis (MS). Pooled polyclonal IgG 
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from the sera of thousands of donors is used to make IVIG that is in turn used 
both for replacement therapy for patients lacking immunoglobulins, and in high 
doses as an anti-inflammatory agent for the treatment of autoimmune diseases 
such as ITP, SLE, MS, and scleroderma (Nimmerjahn and Ravetch, 2007).  
Several models have been proposed to account for the anti-inflammatory activity 
of Fc fragments in IVIG, and one model proposes that sialic acid rich IgG 
facilitates the induction of inhibitory FcγRIIB on effector macrophages, increasing 
the threshold for cell activation, thus reducing inflammation (Nimmerjahn and 
Ravetch, 2007). Enrichment of sialic acid containing IgG significantly lowers the 
amount of IVIG needed for its anti-inflammatory activity (Kaneko et al., 2006). 
The deficiency of sialylated N-glycans on IgG from ST6Gal I deficient mice would 
presumably alter this proposed interaction of Fc-bearing sialic acids with sialic 
acid binding receptors on regulatory macrophages. This in turn may lead to 
reduced ability for IgG derived from ST6Gal I-/- mice to upregulate FcγRIIB on 
effector macrophages.    
 
In addition to changes in the sialylation of IgG, our data also revealed significant 
alterations in the sialylation of IgA (Figure 3.4). In humans, abnormalities in 
galactosylation and sialylation of IgA1 have been reported to play a key role in 
pathogenesis of IgAN. IgA1, which is not produced in mice, is modified by 
ST6GalNAcII, an α2,6 sialyltransferase that modifies O-glycans of the IgA1 hinge 
region (Li et al., 2007b). Reduced expression of ST6GalNAcII has previously 
been reported in peripheral B cells from IgAN patients (Khan et al., 2008).  
However, another report using immortalized B cell lines from IgAN patients 
reached a different conclusion suggesting that ST6GalNAcII was increased in 
expression, while two other glycosyltransferases (C1GalT1 and Cosmc) were 
reduced in expression (Suzuki et al., 2008). The discrepancies in the conclusions 
of the two studies may be due to the different patient groups, and/or differences 
in the cells used in the two studies (peripheral B cells versus immortalized B 
cells) to examine ST6GalNAcII expression. However, it should also be 
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considered that transcriptional regulation of α2,6 sialyltransferases is known to 
be influenced by cell type, differentiation, and transformation status (Hedlund et 
al., 2008; Li et al., 2007b). 
 
Our results using influenza infection of mice deficient in ST6Gal I, the α2,6 
sialyltransferase involved in N-glycan sialylation, demonstrated not only aberrant 
terminal sialylation of N-glycans from ST6Gal I-/- IgA, but also increased 
circulating IgA, and increased IgA deposition in kidney glomeruli. These 
observations would be consistent with early development of an IgAN-like disease 
in ST6Gal I-/- mice. Our findings are reminiscent of the initial study by Berger and 
Hinglais characterizing IgAN (aka Berger’s disease) where they first proposed 
using immuno-fluorescence techniques to diagnose this disease (Berger and 
Hinglais, 1968). In their study, increased glomerular IgA deposition preceded 
disease development, as well as evidence of pathological abnormalities in the 
kidney (Berger and Hinglais, 1968). A recent study proposed that carbohydrates 
of serum IgA may be involved in the development of IgAN-like diseases, 
regardless of whether they are O-or N-glycans, and our data would support this 
conclusion, although the mechanism of pathogenesis remains unclear (Nishie et 
al., 2007). Importantly, while changes in terminal N-glycan sialylation were 
evident in IgG and IgA before influenza infection of ST6Gal I-/- mice, no 
significant differences in immunoglobulin deposition were observed in non-
immunized mice compared to WT mice. Our observations of increased 
deposition were limited to mice with a history of influenza infection. We observed 
no evidence of spontaneous IgAN-like disease development as reported in the 
study of β4GalT I-/- mice (Nishie et al., 2007).  
 
Interestingly, our data is consistent with several familial studies of IgAN that have 
suggested that additional co-factors besides altered glycosylation may be 
required for IgAN disease development, such as respiratory infections (Gharavi 
et al., 2008; Woodroffe et al., 1980). One clinical study showed that patients with 
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IgAN are high responders for IgA production following administration of influenza 
vaccine (Endoh et al., 1984). We also observed higher memory influenza-specific 
IgA responses in ST6Gal I-/- mice compared to WT mice (Figure 3.1). However, it 
remains unclear what mechanisms mediate the increased flu-specific IgA levels 
in ST6Gal I-/- mice.  One possibility is that more IgA-specific plasmablasts are 
generated in ST6Gal I-/- mice, and this accounts for the increased circulating 
levels of IgA. However, our data analyzing the generation of influenza-specific 
IgA plasmablasts showed modest defects in ST6Gal I-/- mice, and influenza-
specific IgA LLPC and MBC numbers were similar comparing WT and ST6Gal I-/- 
immune mice ((Zeng et al., 2009) and data not shown). If so, this would suggest 
that higher IgA levels in influenza immune ST6Gal I-/- mice was more likely due to 
defective IgA clearance, or higher per cell production of IgA. While further studies 
are needed to examine this in more detail, we favor the former explanation since 
it has been proposed that immune complexes of aberrantly glycosylated IgA1 
escape normal clearance mechanisms, and deposit in the renal mesangium 
where they induce glomerular injury in humans (Novak et al., 2008). A similar 
phenomenon may occur with aberrantly glycosylated IgA in ST6Gal I deficient 
mice. Possibly, these mice may provide a useful model by which influenza 
infection, and the generation of under-sialylated IgA (and IgG), can be evaluated 
to determine how genetic remodeling of protein glycosylation and immune history 
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Figure 3. 1. Increased IgA levels in influenza immune ST6Gal I-/- mice. 
C57BL/6 wildtype or ST6Gal I-/- mice remained uninfected or were infected with 
106.8 EID50 of influenza A/HKx31 i.n. and serum, urine, or kidney samples were 
collected. ELISA was performed on samples to measure total or influenza-
specific Ig, or albumin levels. (A) Serum levels were measured of total IgG and 
IgA from naïve, uninfected mice (left), or total IgG, total IgA, and influenza-
specific IgG and IgA from mice at day 175 post-infection (right). (B) Mice were 
serially bled on indicated days and virus-specific IgG and IgA were measured 
longitudinally. (C) Albumin levels were measured in urine from mice at day 400 
post-infection. (D) Kidneys from mice at day 400 post-infection were formalin 
fixed, paraffin-embedded, and thin sections were stained with H&E. Magnification 
600X. Bar graphs show data from n = 4-10 mice, with black bars showing WT 





















































Figure 3. 2.  ST6Gal I-/- mice show greater IgG deposition in glomeruli 
following influenza infection. 
WT or ST6Gal I-/- mice remained uninfected or were infected with 106.8 EID50 of 
influenza A/HKx31 i.n. and on day 400 kidneys were harvested and frozen for 
immuno-histology. (A) Representative staining of IgG in kidney glomeruli from 
naïve WT or ST6Gal I-/- mice (top) compared to WT or ST6Gal I-/- at day 400 
post-infection (bottom).  (B) Mean fluorescence intensity of IgG deposition was 
measured in influenza immune mice. Bar graphs show data from n = 6 samples 
from two independent experiments, with black bars denoting WT and white bars 











Figure 3. 3.  ST6Gal I expression is required for sialylation of N-glycans on 
IgG. 
MALDI-TOF spectra of permethylated N-glycan pools were measured in the 
positive-ion mode. All molecular ions are present in sodiated form [M + Na]+. (A) 
IgG from naive mice, or (B) IgG from mice on day 100 post-infection with 
influenza comparing WT (left) or ST6Gal I-/- (right). Green circle, Man; yellow 
circle, Gal; yellow square, GalNAc; blue square, GlcNAc; red triangle, Fuc; white 






Figure 3. 4. Loss of ST6Gal I expression leads to aberrant IgA 
glycosylation. 
MALDI-TOF spectra of permethylated N-glycan pools were measured in the 
positive-ion mode. All molecular ions are present in sodiated form [M + Na]+. (A) 
IgA and  (B) IgA digested with sialidase S prior to permethylation from influenza 
immune WT (left) or ST6Gal I-/- (right) mice. Green circle, Man; yellow circle, Gal; 
yellow square, GalNAc; blue square, GlcNAc; red triangle, Fuc; white diamond, 




Figure 3. 5. Loss of ST6Gal I expression, concomitant with influenza viral 
infection, result in mesangial IgA deposition. 
WT or ST6Gal I-/- mice remained uninfected or were infected with 106.8 EID50 of 
influenza A/HKx31 i.n. and on day 400 kidneys were harvested and frozen for 
immuno-histology. (A) Representative staining of IgA in kidney glomeruli from 
naïve WT or ST6Gal I-/- mice (top) compared to WT or ST6Gal I-/- at day 400 
post-infection (bottom).  (B) Mean fluorescence intensity of IgA deposition was 
measured in influenza immune mice. Bar graphs show data from n = 6 samples 
from two independent experiments, with black bars denoting WT and white bars 
denoting ST6Gal I-/- mice (** indicates p<0.01).CHAPTER II 
ST6Gal I promotes rapid IL-2Rα surface expression, increasing early proliferation 




ST6GAL I PROMOTES RAPID IL-2Rα  SURFACE EXPRESSION, 
INCREASING EARLY PROLIFERATION OF TERMINAL 




























ST6Gal I is a glycosyltransferase highly expressed by lymphocytes and cancer 
cells that catalyzes the addition of α2,6 sialic acid to galactose (Siaα2-6Gal) on 
N-linked glycoproteins. We discovered that ST6Gal I shows dramatic changes in 
gene expression during memory CD8 T cell differentiation that corresponds with 
lectin binding, but the significance of this regulated carbohydrate modification 
remained elusive. To identify the role of these regulated glyco-phenotypic 
changes, we infected ST6Gal I-/- mice and show that viral-specific T and B cell 
expansion was impaired. Moreover, defective viral-specific CD8 T cell expansion 
was due to early intrinsic defects in proliferation of terminal effector cells, 
whereas memory precursor development was enhanced. We provide direct 
evidence that loss of ST6Gal I expression by CD8 T cells resulted in delayed 
surface expression of IL-2Rα in vivo due to impaired IL-2/IL-2R signaling. These 
results suggest that CD8 T cells regulate ST6Gal I expression to promote 


















Over the past several decades it has been appreciated that lymphocytes show 
dramatic changes in lectin binding during development and differentiation 
(Galvan et al., 1998b; Harrington et al., 2000; London et al., 1978; London and 
Horton, 1980; Onami et al., 2002; Rose et al., 1980; Rose et al., 1981). Changes 
in lectin binding properties were exploited before the wide availability of 
monoclonal antibodies, allowing for the routine purification of cell subsets. For 
example, peanut agglutinin (PNA) which recognizes (Galβ1-3GalNAc) on O-
linked glycans was used to distinguish developing CD4+CD8+ thymocytes from 
SP mature T cells, as well as germinal center B cells from naïve, resting B cells 
(London et al., 1978; London and Horton, 1980; Rose et al., 1980). More 
recently, effector and memory T cell populations were shown to bind PNA highly, 
while naïve T cells showed much weaker binding by this lectin (Galvan et al., 
1998b; Onami et al., 2002). Additionally, naïve, effector, and memory T cell 
populations show changes in CD43 glycoform expression which can be 
visualized by changes in binding with the glycosylation-dependent monoclonal 
antibody, 1B11 (Harrington et al., 2000; Onami et al., 2002). Although little is 
known about the significance of altered glycosylation in T cell activation and 
function, several studies have demonstrated that changes in the gene expression 
of specific glycosyltransferases are responsible for glyco-phenotypic changes 
observed in T cell populations (Comelli et al., 2006; Priatel et al., 2000). These 
studies suggest that precise regulation of enzyme expression occurs during T 
cell development, activation, and differentiation, and is often responsible for 
observed glyco-phenotypic changes. However, the functional significance of 
these glyco-phenotypic changes has remained poorly understood. 
 
Alterations in glycosylation have been defined in several immune-mediated 
diseases, immuno-deficiencies, and cancer. Among the best-studied examples 
include the recruitment of leukocyte populations to lymphoid organs and sites of 
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infection, which is critically dependent on fucosylated, sialylated glyco-conjugates 
such as the sialyl Lewis X (sLex) structure (Harp and Onami, 2010; Lowe, 2003). 
A leukocyte adhesion deficiency disease, LADII (also known as congenital 
disorder of glycosylation IIc of CDG-IIc) is caused by mutations in a GDP-fucose 
transporter (SLC35C1), resulting in hypo-fucosylation of glycoproteins, and 
consequent impairment in leukocyte interaction with vascular endothelium (Luhn 
et al., 2001). In cancer, one of the hallmark features of malignant cells is altered 
sialylation, and specific glycan structures are commonly used as markers of 
tumor progression (Varki, 2008). ST6Gal I, a glycosyltransferase that catalyzes 
the addition of α2,6 sialic acid to galactose (Siaα2-6Gal) on N-linked 
glycoproteins, is up-regulated by oncogenic ras, and shows high expression in 
several tumors including cervical, colorectal, breast, and hepatocellular tumors 
(Dall'Olio et al., 2004; Hedlund et al., 2008; Vazquez-Martin et al., 2005; Wang et 
al., 2002). Several studies have suggested that ST6Gal I expression regulates 
tumor cell differentiation, motility, and migration (Christie et al., 2008; Hedlund et 
al., 2008; Qian et al., 2009; Seales et al., 2005). 
  
To gain insight into the glyco-phenotypic changes that occur following T cell 
activation in vivo, we undertook a comprehensive examination of 
glycosyltransferase gene expression during memory CD8 T cell differentiation 
using the NIGMS Consortium for Glycomics Glyco-gene chip. We identified 
changes in glyco-specific gene expression, including changes in the expression 
of the sialyltransferase ST6Gal I, which showed a striking decrease during the 
naïve to effector cell transition. In contrast to the results observed in T cells, B 
cells do not show dramatic reduction in ST6Gal I expression following B cell 
activation (Comelli et al., 2006; Zeng et al., 2009). We confirmed that changes in 
ST6Gal I expression in CD8 T cells were accompanied by concomitant changes 
in cell surface glycosylation, using the lectin Sambucus nigra agglutinin (SNA) 
that recognizes the Siaα2-6Gal linkage created by ST6Gal I on N-linked glycans. 
Surprisingly, SNA defined heterogeneity in memory CD8 T cells, with SNAhigh 
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and SNAlow memory CD8 T cell populations present in all tissues following viral 
resolution. Extensive comparison of SNAhigh and SNAlow memory CD8 T cells 
with regard to other markers of effector or memory T cells failed to identify any 
other marker that uniquely distinguished these populations. However, these two 
populations differed with respect to extent of proliferation and kinetics of viral 
clearance, suggesting functional heterogeneity within the memory CD8 T cell 
compartment. 
 
To further investigate the importance of ST6Gal I regulation during memory CD8 
T cell differentiation, we undertook a detailed analysis of LCMV-specific 
responses in ST6Gal I deficient mice. These studies identified early impairments 
in viral-specific T and B cell responses. Strikingly, we observed that expansion of 
short-lived effector cell (SLEC) or terminal effector populations were significantly 
impaired, while ST6Gal I-/- T cells preferentially developed into memory precursor 
effector (MPEC) populations. We generated transgenic P14xST6Gal I-/- mice, to 
obtain CD8 T cells specific for the GP33-41 peptide of the LCMV glycoprotein, to 
probe cell intrinsic defects. We discovered that CD8 T cell loss of ST6Gal I 
expression resulted in defective early proliferation, and this defective proliferation 
was not due to defective T cell recruitment, but rather altered kinetics of IL-2Rα 
up-regulation and surface expression in the initial 24hrs following antigen 
exposure. We further show that this was due to impaired IL-2/IL-2Rα signaling. 
Our results provide the first direct evidence that regulation of a 
glycosyltransferase responsible for post-translational carbohydrate modification 
of several T cell glycoproteins, influences early T cell proliferation by fine-tuning 






Materials and Methods 
 
Mice and immunizations 
All animals were handled in strict accordance with good animal practice as 
defined by the University of Tennessee IACUC committee, and the committee 
approved all animal work. ST6Gal I-deficient mice were originally generated by J. 
Marth (University of California, San Diego) and obtained from the Consortium for 
Functional Glycomics and bred in-house, backcrossed to C57BL/6 x10 
generations (Hennet et al., 1998). Transgenic P14 Thy1.1 mice were kindly 
provided by Dr. Rafi Ahmed (Emory Vaccine Center, GA) and bred in-house. 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). 
Mice were maintained under specific pathogen-free conditions at the University 
of Tennessee in accordance with university IACUC guidelines. Mice were 
infected with 2×105 PFU LCMV-Armstrong intra-peritoneal (i.p.) or intravenous 
(i.v.) as indicated. For memory re-challenge experiments, mice were re-




All antibodies were purchased from BD-Pharmingen (La Jolla, CA). SNA-FITC 
was purchased from Sigma Chemicals (St. Louis, MO). DbGP33-41 MHC 
tetramers were prepared as previously described (Murali-Krishna et al., 1998) or 
provided by the NIH Tetramer Facility (Atlanta, GA). P14xThy1.1 chimeric mice 
were generated as previously described (Suvas et al., 2007). Briefly, 0.5-1x106 
total Thy1.1 P14 transgenic spleen cells were adoptively transferred into intact 
C57BL/6 mice followed by infection with 2x105 PFU of LCMV-Armstrong i.p.  
For single transfer experiments, ST6Gal-I+/- x P14 Tg+ Thy 1.1-1.2+ (Tg WT) and 
ST6Gal-I-/- x P14 Tg+ Thy 1.1-1.2+ (Tg KO) mice were sacrificed, spleens were 
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collected, and processed to yield a single cell suspension. 1x106 Tg WT or Tg 
KO cells in 0.5 ml PBS were injected into naïve C57BL/6 Thy1.2+ recipient mice 
by tail vein (i.v.) injection. Recipient mice were infected with 2x105 pfu/ml LCMV 
Armstrong i.p. or i.v. the next day. Mice were sacrificed at day 8 post- infection 
and spleens were collected, processed, and single cell suspensions were stained 
with fluorochrome conjugated anti-Thy1.1, anti-Thy1.2, anti-CD8 antibodies, 
SNA, and DbGP33-41 MHC-I tetramer for analysis by flow cytometry. All samples 
were run on a FACSCalibur (BD Biosciences) and analyzed using FlowJo 
software (Tree Star). Total number of donor cells in recipient mice was calculated 
from the percent of Thy1.1-1.2+DbGP33-41+CD8+ cells in total splenocytes. 
Unpaired t tests were performed to determine statistical significance, with *** 
denoting p<0.001, ** denoting p<0.01, and * denoting p<0.05. 
 
For competition co-transfers, ST6Gal I+/- x P14 Tg+ Thy 1.2+ (Tg WT) and ST6Gal 
I-/- x P14 Tg+ Thy 1.1-1.2+ (Tg KO) mice were sacrificed, spleens were collected, 
and processed to yield a single cell suspension. A 1:1 mixture of Tg WT and Tg 
KO cells in a total of 1x106 cells in 0.5 ml PBS per mouse were transferred into 
recipient C57BL/6 Thy1.1+ mice i.v. Recipient mice were infected with 2x105 
pfu/ml LCMV Armstrong i.p. 24 hours following adoptive transfer. Mice were 
sacrificed at day 8 post-infection, spleens were collected, processed, and single 
cell suspensions were stained and analyzed as above.  
For memory functional experiments, SNAhigh, SNAlow, or total Thy1.1+ CD8+ T 
cells were FACS sorted using a FACS Advantage (BD La Jolla, CA) from 
immune (day 100) P14xThy1.1 chimeric mice, and 2x104 sorted memory T cells 
were adoptively transferred into C57BL/6 mice, followed by challenge with 2x106 
LCMV clone 13 i.v. Mice were serially bled and serum and PBMC were analyzed 




DNA Microarray Hybridization 
Total RNA was isolated from FACS sorted Ag-specific CD8 T cells in TRIZOL 
(Gibco/Invitrogen, Rockville, MD) according to manufacturer’s protocol. The 
cDNA was synthesized using Superscript Choice cDNA Synthesis Kit 
(Gibco/Invitrogen, Rockville, MD) and an oligo(dT) primer containing a T7 
promoter. The MEGAscript T7 kit (Ambion, Austin, TX) was used to amplify 
cRNA from the cDNA. The cRNA was reverse transcribed with fluorescently 
labeled nucleotides and hybridized to the Glyco-gene chip at the Scripps 
Research Clinics Microarray Core as part of the CFG (La Jolla, CA). 
 
In vivo CFSE proliferation assay 
ST6Gal-I+/- x P14 Tg+ Thy 1.1 and ST6Gal-I-/- x P14 Tg+ Thy 1.1 mice were 
sacrificed, spleens were collected, and processed to yield single cell suspensions 
of 107 cells/ml in RPMI media. CD8 T cells were isolated by negative purification 
using a CD8 T cell isolation kit (Miltenyi Biotec, Germany) following 
manufacturer’s instructions. Briefly, 2x107 splenocytes were incubated with a 
cocktail of magnetic biotin-conjugated antibodies against non-CD8 T cells, 
washed, and passed through a MACS LS column placed on a MACS magnetic 
separator to deplete the magnetically labeled cells, followed by three rinses with 
MACS buffer. Untouched CD8 T cells were collected, washed, and counted. 
These purified CD8 T cells were re-suspended at 1x107 cells/ml in PBS and 
incubated with 5µM final concentration of CFSE in PBS for 3 minutes at room 
temperature, mixed, and incubated for 4 more minutes. Fetal calf serum 
(Hyclone, Logan, UT) was added at a final 10% concentration, mixed, and 
incubated for 3 minutes, followed by addition of complete RPMI. CFSE labeled-
CD8 T cells from Tg WT or Tg KO mice were re-suspended in PBS, and 5x105 
cells in 0.5 ml PBS were injected i.v. into naïve Thy1.2+ C57BL/6 recipient mice, 
followed by infection with 2x105 PFU LCMV Armstrong i.p. the next day. 
Recipient mice were sacrificed at day 3 post-infection and splenocytes were 
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stained with anti-CD8 and anti-Thy1.1 antibodies, and CFSE intensity was 
measured by flow cytometry. 
 
In vitro assays 
Activation and proliferation: Spleen cells were isolated from ST6Gal-I+/- x P14 Tg+ 
Thy 1.1 and ST6Gal-I-/- x P14 Tg+ Thy 1.1 mice. 2x105 spleen cells were 
incubated with 0.01ug/ml GP33-41 peptide in 96-well plates, in triplicate. Cells 
were harvested as indicated, fixed, and stained as previously described (Kalia et 
al., 2010). 
Vaccinia plaque assay: Plaque assays were performed on homogenized ovaries 




Dramatic changes in expression of the glycosyltransferase ST6Gal I during 
memory T cell differentiation 
To examine glycosyltransferase gene expression during memory T cell 
differentiation, we used P14.Thy1.1 TCR transgenic CD8 T cells, specific for the 
GP33-41 peptide of the LCMV envelope glycoprotein and interrogated gene 
expression using the NIGMS Consortium for Glycomics (CFG) Glyco-chip that 
contains probe sets to ~1800 murine and human glycosylation-related genes. 
Naïve CD8 T cells were obtained directly from uninfected transgenic mice, while 
Ag-specific effector and memory populations were generated following adoptive 
transfer and infection of C57BL/6 Thy1.2 mice as previously described (Kaech et 
al., 2002). Isolation of CD8+Thy1.1+ cells at various times post-infection yielded 
pure populations of T cells with the same TCR specificity undergoing progressive 
differentiation into memory cells. Gene expression profiles were analyzed and 
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the results are available online (http://www.functionalglycomics.org/). Of ~50 
glycosylation-specific genes that showed changes in gene expression, several 
were glycosyltransferases. One glycosyltransferase, ST6Gal I, showed a greater 
than 20-fold reduction in expression comparing day 8 effector cells to naïve cells 
(Figure 4.1A). However, this expression increased during the transition from day 
8 effector cells to day 100 memory cells, with memory cells showing an 
intermediate expression compared to naïve and effector cells (Figure 4.1B).  
 
To analyze CD8 T cell surface expression of (Siaα2-6Gal) modifications, we 
used the elderberry bush derived lectin, Sambucus nigra agglutinin or SNA. 
FACs analysis revealed that changes in St6gal1 gene expression were 
accompanied by concomitant glyco-phenotypic changes in lectin binding (Figure 
4.1B). Naïve CD8 T cells were uniformly SNAhigh, while day 8 effector CD8 T cells 
were uniformly SNAlow. Interestingly, memory CD8 T cells were heterogeneous, 
with the population showing both SNAhigh and SNAlow populations (Figure 4.1B). 
 
We have previously demonstrated that unlike CD8 T cells, SNA binding remained 
uniformly high on naïve resting B cells, plasma cells (PC), and germinal center 
(GC) B cells following viral infection (Zeng et al., 2009). Our data supported 
previously published work analyzing terminal sialylation of N-linked glycans of B 
cells activated in vitro using MALDI-TOF mass spectrometry (Comelli et al., 
2006). To query whether CD4 T cells also undergo glyco-phenotypic changes 
during activation and differentiation in vivo similar to CD8 T cells, we examined 
SNA binding of CD4 T cell populations following viral infection.  As expected, 
naïve (CD44low) CD4 T cells were also uniformly SNAhigh similar to naïve CD8 T 
cells and resting B cells (Figure 4.1C). However, we discovered that at day 8 
following LCMV infection, CD4 T cell populations diverged, showing unique 
glyco-phenotypic changes compared to other immune cell populations. Similar to 
GC B cells and plasma cells, CXCR5+ T follicular helper cells at day 8 were 
SNAhigh (Figure 4.1C). In contrast, the Ag-specific CD4 T cell population at day 8 
105 
 
was heterogeneous with both SNAhigh and SNAlow GP61-80 specific CD4 T cells 
(Figure 4.1C). Memory Ag-specific CD4 T cells were mostly SNAhigh, in contrast 
to CD8 memory T cells, which were heterogenous with mostly SNAlow (~70%), 
and a sub-population of SNAhigh memory CD8 T cells. Overall, CD8, CD4, and B 
cell populations show unique patterns of SNA lectin binding following cell 
activation in vivo. Our observations of unique SNA-binding changes among Ag-
specific CD4 T cell populations support and extend recent work showing that 
different T helper populations show differences in ST6Gal I expression and SNA 
binding (Toscano et al., 2007).  
   
We further explored the heterogeneous nature of the memory CD8 T cell 
population by examining expression of other cell markers that have been shown 
to change during memory differentiation such as CD62L and 1B11, but found no 
correlative binding (unpublished data). We were unable to identify any other 
marker that uniquely identified these two subpopulations.  To determine whether 
there were any functional differences between these two memory T cell subsets, 
we sorted memory CD8 T cell populations into SNAhigh or SNAlow populations, 
adoptively transferred them into recipient mice, and infected these mice with 
LCMV clone 13 (Figure 4.1D). Serum and PBMCs were collected from each 
group, and viral titers and Ag-specific T cells were measured. While all groups of 
mice that received memory T cell populations cleared virus by day 15, mice that 
received SNAhigh memory CD8 T cell populations showed faster kinetics of viral 
clearance and increased early proliferation compared to mice that received 
SNAlow memory populations (Figure 4.1E, 1F). These data suggested that 
ST6Gal I expression by CD8 T cells may promote faster viral-specific responses. 
 
Impaired viral-specific responses in ST6Gal I-deficient mice 
Since SNAhigh memory CD8 T cells showed evidence of more rapid viral specific 
responses, we investigated viral specific T cell responses in ST6Gal I-/- mice. 
106 
 
ST6Gal I-/- mice were generated several years ago and show mostly normal T 
and B cell development, but display impaired T-dependent and T-independent 
humoral responses (Hennet et al., 1998; Zeng et al., 2009). Defective B cell 
responses in these mice can be rescued by genetic ablation of the Siaα2-6Gal 
specific mammalian lectin CD22, a negative regulator of BCR signaling (Collins 
et al., 2006; Grewal et al., 2006).  
 
ST6Gal I-/- and C57BL/6 WT mice were infected with 2x105 pfu LCMV-Armstrong 
(Figure 4.2). We measured significant impairments in the generation of LCMV-
specific CD8 T cell responses, LCMV-specific CD4 T cell responses, and LCMV-
specific humoral responses in ST6Gal I-/- mice at day 8 (Figure 4.2A). When we 
examined Ag-specific CD8 T cells on day 8, we noted that several memory 
effector precursor (MPEC) markers were more highly expressed on CD8 T cells 
of ST6Gal I-/- mice, including CD127 (IL-7Rα) (Figure 4.2B). When we compared 
terminal effector or short-lived effector cell (SLEC) populations 
(KLRG1highCD127low), we noted that this population was significantly reduced in 
ST6Gal I-/- mice, whereas MPEC numbers were similar (Figure 4.2C). When we 
calculated the ratio of these populations at day 8, we found that 5-10% of the 
total day 8 CD8 T cells were memory precursors in WT mice, while in ST6Gal I-/- 
mice 40-45% of total day 8 CD8 T cells were memory precursors (Figure 4.2C). 
Consistent with the higher ratio of memory precursors, measurement of Ag-
specific CD8 and CD4 T cell populations at memory revealed that memory T cell 
generation was not impaired in ST6Gal I-/- mice, despite reduced T cell 
expansion at day 8 (Figure 4.2D). Examination of functional memory by analysis 
of re-call responses following infection of immune WT and ST6Gal I-/- mice with 
recombinant Vaccinia expressing GP33 (VV-GP33) showed that ST6Gal I-/- mice 
generated similar numbers at day 3 of re-call and showed similar viral control 
(Figure 4.2E).  Taken together, the loss of ST6Gal I significantly impaired early 
viral-specific T cell responses, however a greater proportion of the CD8 T cell 




T-bet regulates St6gal1 expression 
Our discovery that terminal effector or SLEC expansion was reduced in ST6Gal I 
-/- mice (Figure 4.2C) prodded us to examine gene expression in effector subsets 
since our earlier studies analyzing total day 8 effectors potentially obscured 
differences in recently identified SLEC and MPEC subset populations (Joshi et 
al., 2007) (Figure 4.1). Comparison of KLRG1highIL-7Rlow (SLEC) to KLRG1lowIL-
7Rhigh (MPEC) CD8 T cells at day 6-8 revealed that MPECs have higher 
expression of St6gal1 (Figure 4.3A). However, this difference in expression may 
be due to greater down-regulation of St6gal1 in SLEC. Since several 
transcriptional regulators have recently been identified as differentially expressed 
in effector subsets, and high levels of certain transcriptional regulators (eg. T-bet, 
Blimp-1) promote effector CD8 T cell terminal differentiation (Rutishauser and 
Kaech, 2010), we queried whether loss of T-bet expression influenced St6gal1 
expression. 
 
T-bet expression increases dramatically upon activation of naive T cells, with 
higher expression in SLECs compared to MPECs (Kalia et al., 2010; Pipkin et al., 
2010; Rutishauser and Kaech, 2010). Examination of T-bet-/- SLECs compared to 
MPECs revealed similar expression of St6gal1 (Figure 4.3B left panel). Thus, T-
bet expression was required for differential expression of St6gal1 in SLEC versus 
MPEC populations. Further, comparing St6gal1 expression in WT MPECs versus 
T-bet-/- MPECs, T-bet-/- memory precursors expressed ~12-fold higher St6gal1, 
while T-bet-/- SLEC expressed ~80-fold higher St6gal1 compared to WT SLEC 
(Figure 4.3B middle and right panel). These data provided evidence that T-bet 
expression regulates the expression St6gal1, where loss of T-bet expression 
results in increased St6gal1 expression in effector subsets. However, we do not 
yet know if this repression by T-bet is direct or indirect, for example if T-bet 




Interestingly, day 8 TFH cells remained SNAhigh (Figure 4.1C) and this population 
of T cells has been shown to express Bcl-6, the mutually antagonistic 
transcriptional repressor of Blimp-1 and T-bet (Johnston et al., 2009; Rutishauser 
and Kaech, 2010).  ST6Gal I-/- mice showed more disorganized T cell zones in 
splenic B cell follicles at day 8 post-infection, with variably dispersed CD4 T cells 
(Figure 4.4). 
 
Impaired CD8 T cell expansion is cell intrinsic 
Since we observed reduced expansion of CD8 T cells in ST6Gal I-/- mice (Figure 
2A), but also reductions in other viral-specific lymphocyte populations, such as 
CD4 T cells and B cells which influence CD8 T cell expansion (Crawford et al., 
2006), we were unsure whether defective CD8 T cell expansion in these mice 
was cell autonomous. To understand if reduced expansion of CD8 T cells lacking 
ST6Gal I was due to cell intrinsic defects, we generated transgenic P14xST6Gal 
I-/- mice (Figure 4.5A). CD8 T cells from these transgenic mice were adoptively 
transferred into recipient C57BL/6 Thy1.2 mice and Ag-specific responses were 
evaluated.  As shown in Figure 4.5B, we observed significantly reduced 
expansion at day 8 of Ag-specific CD8 T cells that lacked ST6Gal I, with a larger 
fraction of the endogenous/host response contributing to the DbGP33-41 CD8 
specific response. To further examine this, we performed a competitive in vivo 
assay and adoptively transferred equal numbers of P14xST6Gal I+/- and 
P14xST6Gal I-/- CD8 T cells into the same C57BL/6.PL (Thy1.1) recipient mice 
(Figure 4.5C).  As before, Ag-specific CD8 T cells that expressed ST6Gal I 
showed greater expansion at day 8, with significantly higher frequencies 
compared to CD8 T cells that did not express ST6Gal I. These data provided 
evidence that ST6Gal I expression by CD8 T cells was required for optimal CD8 




These observations of reduced numbers of Ag-specific CD8 T cells at day 8 did 
not distinguish whether the reduced numbers of ST6Gal I-/- CD8 T cells were due 
to reduced proliferation or increased apoptosis in vivo. To determine whether 
reduced expansion was due to decreased proliferation, P14xST6Gal I+/- and 
P14xST6Gal I-/- CD8 T cells were purified and CFSE labeled. These labeled cells 
were then adoptively transferred into C57BL/6 recipient mice, and CFSE dilution 
was measured at day 3 post-infection with LCMV. As shown in Figure 4.5D, CD8 
T cells that lacked expression of ST6Gal I, showed diminished proliferation, with 
a greater number of undivided CD8 T cells. Taken together, these data show that 
loss of ST6Gal I expression by CD8 T cells resulted in reduced expansion due to 
impaired CD8 T cell proliferation. 
 
Similar recruitment and T cell activation, but delayed IL-2Rα expression of 
ST6Gal I-/- CD8 T cells 
Since our data showed that ST6Gal I deficient CD8 T cells trailed in division of 
ST6Gal I expressing CD8 T cells following antigen exposure, we examined 
proliferation in more detail. We hypothesized that the reduced proliferation could 
be due to a delay in recruitment of ST6Gal I-/- CD8 T cells into the viral specific 
response. Loss of expression of ST6Gal I by CD8 T cells results in a reduction of 
sialylated biantennary N-glycans, and may lead to differential recognition of T 
cells by antigen-presenting cells expressing glycan binding proteins (GBPs) that 
recognize sialylated N-glycans (Comelli et al., 2006). Examples of GBPs that 
bind sialic acids include CD22 (aka siglec-2) and CD169 (aka siglec-1, 
sialoadhesin, or MOMA-1), which are expressed by B cells and marginal zone 
macrophages, respectively; both CD22+ B cells and CD169+ macrophages have 
been suggested to play a role in T cell activation (Collins et al., 2004; Junt et al., 
2007; Oehen et al., 2002; Oetke et al., 2006; van den Berg et al., 1992). Since 
several studies have suggested that ST6Gal I expression by tumor cells 
influences cell motility and migration, we hypothesized that loss of ST6Gal I 
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expression was inhibiting interaction with CD169+ expressing marginal zone 
macrophages or other siglec-expressing APCs in vivo, leading to reduced 
recruitment of ST6Gal I-/- CD8 T cells into the immune response (Junt et al., 
2007; Kumamoto et al., 2004; Qian et al., 2009). The magnitude of an adaptive 
immune response is regulated by the number of cells that are recruited from the 
naïve repertoire, and the burst size of participating clones (van Heijst et al., 
2009). If recruitment of naïve CD8 T cells was impaired by the loss of ST6Gal I, 




We examined early T cell activation in vivo. Here we adoptively transferred 
P14xST6Gal I+/- versus P14xST6Gal I-/- CD8 T cells into WT recipient mice, 
monitored CD8 T cell expansion and surface expression during the first hours 
and days of viral infection, and focused on early activation markers CD69 and 
CD25. CD69 expression comes up rapidly on T cells following TCR stimulation, 
while expression of CD25, the α chain of the high affinity IL-2R, is regulated both 
by TCR signaling and IL-2/IL-2R signaling via STAT5 (Malek TR, 2008).  We 
included analysis of the IL-2R because of its pivotal role in T cell proliferation, its 
recently recognized role in memory T cell programming, and evidence that this 
receptor is a substrate for ST6Gal I (Leonard et al., 1983; Malek et al., 1995). As 
shown in Figure 4.6A, by day 5 Ag-specific CD8 T cells expressing ST6Gal I 
have increased ~700-fold, and consistent with earlier data, Ag-specific CD8 T 
cells lacking expression of ST6Gal I show significantly less expansion. However, 
when we examined T cell activation and recruitment into the immune response, 
we observed that in the first 12 hours, activation of the transferred CD8 T cells 
occurred similarly, with identical kinetics for CD69 and CD25 (Figure 4.6B, C left 
panels).  By 24 hours post-infection, CD69 expression is high on all transferred 
CD8 T cells regardless of expression of ST6Gal I (Figure 4.6B). Similar results 
were seen analyzing CD44 and CD62L (unpublished data). This data provided 
111 
 
strong evidence that recruitment and activation of ST6Gal I-/- Ag-specific CD8 T 
cells was not impaired. However, examination of CD25 expression revealed that 
surface expression of the IL-2Rα chain was delayed from 12-24 hrs in Ag-
specific CD8 T cells that did not express ST6Gal I (Figure 4.6C, right panel).  
Thus, these data suggested that ST6Gal I expression by naïve CD8 T cells 
promoted rapid and prolonged IL-2Rα expression, which would contribute to 
early and more extensive proliferation of terminal effectors (Kalia et al., 2010).  
 
IL-2/IL-2R signaling and surface expression is impaired in ST6Gal I-/- CD8 T 
cells 
CD25 (IL-2Rα) expression is regulated by signals through both the TCR and the 
IL-2R, so defects in either TCR signaling, IL-2R signaling, or both, may contribute 
to impaired surface expression of this receptor chain. We observed no 
differences in TCR stimulation in vivo comparing ST6Gal I-expressing and 
ST6Gal I-deficient Ag-specific CD8 T cells during the first 24 hours of viral 
infection (Figure 4.6B). CD25 expression was similar in the initial 12 hours of viral 
infection, but was different in the ensuing 12-24 hours post-infection (Figure 
4.6C). Previous reports have demonstrated that IL-2 splenic concentrations peak 
within the first day of LCMV infection (Kalia et al., 2010). Based on these data, 
we formulated a new hypothesis where we considered TCR signaling resulted in 
normal CD25 expression by ST6Gal I-/- CD8 T cells, however IL-2/IL-2R signaling 
was impaired, resulting in diminished CD25 expression.  
 
To test this, we examined in vitro proliferation of P14xST6Gal I+/- versus 
P14xST6Gal I-/- CD8 T cells following GP33-41 peptide stimulation (Figure 4.7A). 
Cell clusters were smaller in P14xST6Gal I-/- CD8 T and we confirmed our 
observation of reduced proliferation of these cells (Figure 4.7A). Peptide 
stimulated Ag-specific CD8 T cells made similar amounts of IL-2, TNFa, and 
IFNg, similar to results we found in vivo (unpublished data). Cell viability dropped 
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significantly during the first day of in vitro culture of both WT and ST6Gal I-/- CD8 
T cells, and ST6Gal I-/- CD8 T cells showing significantly reduced viability (Figure 
4.7B).  
 
We then examined early activation, comparing expression of CD25 and 
phosphorylated STAT5 (pSTAT5). We stimulated P14xST6Gal I+/- or 
P14xST6Gal I-/- CD8 T with GP33-41 peptide and IL-2, or IL-2 only. Addition of 
IL-2 to the culture conditions significantly increased viability of both WT and 
ST6Gal I-/- CD8 T cells and was dose-dependent (unpublished data). As shown 
in Figure 7C, in the presence of GP33-41 peptide, both P14xST6Gal I+/- and 
P14xST6Gal I-/- CD8 T showed similarly high percentages of CD25high cells, 
although total MFI was reduced for ST6Gal I-/- CD8 T cells. ST6Gal I-/- CD8 T 
cells showed no difference in pSTAT5 following peptide stimulation (Figure 
4.7D). CD8 T cells cultured with IL-2 only showed lower expression of CD25 
compared to peptide stimulated cells (Figure 4.7C). However, analysis of ST6Gal 
I-/- CD8 T cells revealed that these cells had fewer CD25high cells and lower 
pSTAT5 compared to ST6Gal I+/- CD8 T cells (Figure 4.7C-D). These data 
provided evidence that IL-2/IL-2R signaling was impaired in ST6Gal I-/- CD8 T 
cells, inhibiting IL-2Rα expression.  
 
Taken together, our data suggests that CD8 T cells regulate ST6Gal I to promote 
expression of IL-2Rα following IL-2/IL-2R signaling, leading to more rapid 
expression of the high affinity IL-2 receptor on Ag-specific CD8 T cells. This 
earlier and prolonged expression of IL-2Rα by naïve CD8 T cells appears to 
favor proliferation and differentiation of short-lived effectors. Our data provides 
the first evidence that a specific carbohydrate modification, the addition of α2,6-
linked N-glycans, appears to fine-tune responses through the IL-2R, thus 






Essentially all mammalian cells are covered with a dense, complex array of 
oligosaccharides or sugars termed the glycocalyx, through which the cell 
interacts with its environment (Varki, 2008). Many cell surface glycoprotein 
receptors have significant numbers of N-glycan sites, and recent work has shown 
that both the complexity and numbers of N-glycans can regulate cell proliferation 
and differentiation (Lau et al., 2007). Sialic acids are typically found on the 
outermost end of glycan chains, and given their wide distribution, can modulate a 
variety of normal and pathological processes (Varki, 2008). N-linked sialylation in 
particular, has been suggested to play a significant role in tumor biology, 
modulating growth and differentiation of carcinomas (Hedlund et al., 2008). 
 
Following T cell activation in vivo, T cells undergo an exponential growth phase, 
characterized by gene expression changes and glyco-phenotypic changes 
(Kaech et al., 2002; Murali-Krishna et al., 1998; Onami et al., 2002). These cells 
differentiate into effector cells, and a subset become memory T cells (Joshi et al., 
2007). We discovered using a microarray analysis that ST6Gal I, 
sialyltransferase expressed in the Golgi that is responsible for α2,6-sialylation on 
N-glycans, was differentially expressed during memory CD8 T cell differentiation 
and showed concomitant changes in surface SNA lectin binding (Figure 4.1).  
Moreover, we found that T cells expressing St6gal1 showed more proliferative 
capacity, while those lacking St6gal1 expression divided less and showed slower 
growth (Figures 4.2 and 4.5). T-bet repressed expression of St6gal1, and lower 
expression of St6gal1 was observed in terminally differentiated effector 
populations, or SLECs (Figure 4.3). Interestingly, tumors that lacked expression 
of St6gal1 also showed more terminal differentiation (Hedlund et al., 2008). In 
contrast, memory precursor and memory T cells, which retain their stem cell-like 
proliferative capacity, have higher expression of St6gal1 compared to effector T 
cells (Figure 4.1 and 4.3). Similarly, tumors expressing St6gal1 are less 
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differentiated and increased St6gal1 expression correlated with poor prognosis 
(Hedlund et al., 2008).   
 
IL-2 is tightly regulated due to its potent stimulatory properties, and is typically 
produced by recently activated T cells, acting in an autocrine or paracrine fashion 
(Letourneau et al., 2010). CD25 has recently been suggested to play an 
unanticipated role in the regulation of IL-2 homeostasis (Letourneau et al., 2010). 
Most IL-2 production in vivo occurs in secondary lymphoid organs and evidence 
suggests it is likely consumed there by proliferating CD25/IL-2Rα+ T cells 
(Letourneau et al., 2010). Prolonged CD25/IL-2Rα expression on virus-specific 
CD8 T cells has been shown to favor the differentiation of terminal effectors 
(Kalia et al., 2010; Pipkin et al., 2010). CD25high CD8 T cells show more 
extensive early proliferation in vivo, while CD8 T cells with lower expression of 
CD25 are relatively less sensitive to IL-2, and give rise to long-lived memory cells 
(Kalia et al., 2010). In ST6Gal I-/- mice, we observed that expansion of SLECs 
was compromised, while memory precursor development was enhanced (Figure 
4.2). CD25/IL-2Ra expression was delayed on ST6Gal I-/- CD8 T cells and we 
present evidence that the delay in surface expression of the high affinity IL-2Rα 
on activated ST6Gal I-/- CD8 T cells was likely attributable to defective IL-2/IL-2R 
induced expression of IL-2Ra (Figure 4.6 and 4.7). Thus, early proliferation was 
reduced. However, a greater proportion of the ST6Gal I-/- CD8 T cell effector 
population was memory precursors (Figure 4.2). Thus, despite lower overall CD8 
T cell expansion, function and number of memory T cells was comparable in 
ST6Gal I-/- mice. Thus St6gal1 expression is not required for memory T cell 
differentiation, but is required for optimal proliferation of terminally differentiated 
effectors or SLECs. 
 
St6gal1 expression is significantly down-regulated following activation of CD8 T 
cell populations compared to naïve CD8 T cells, and we speculate based on our 
data that for naïve CD8 T cells, the function of high St6gal1 expression is to 
115 
 
amplify signals through the IL-2 receptor, promoting greater proliferation. In 
contrast, activated CD8 T cells may limit this amplification of IL-2 signals by 
reducing expression of this sialyltransferase and consequently altering N-linked 
sialylation of ST6Gal I glycoprotein substrates. The α and β chains of IL-2R have 
been shown to be N-glycosylated and sialylated, and changes in glycosylation 
may change competition for this cytokine receptor in its heterodimeric (βγ) or 
heterotrimeric (αβγ) forms (Asao et al., 1990; Leonard et al., 1983; Opdenakker 
et al., 1995). Glycosylation of cytokines or cytokine receptors influences specific 
biological activities, with several studies asserting that glycosylation attenuates 
cytokine activity (Opdenakker et al., 1995). Since recent work suggests that 
sustained IL-2R signaling drives terminal effector differentiation, the reduction in 
St6gal1 expression may limit these signals, switching to the promotion of 
functional long-lived memory differentiation. These memory precursors may 
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Figure 4. 1. Dramatic changes in expression of the glycosyltransferase 
ST6Gal I during memory T cell differentiation. 
1x106 Thy1.1+ DbGP33-41 specific transgenic splenocytes were adoptively 
transferred into C57BL/6 mice and these mice were infected with 2x105 pfu 
LCMV Armstrong i.p. CD8 T cell populations were then enriched from 
splenocytes from naïve transgenic mice (day 0) or day 8, day 15, day 22, or day 
100 post-infection chimeric mice by depletion with MHC class II and CD4 beads. 
Thy1.1+ CD8+ T cells were then FACS sorted to greater than 94% purity and 
mRNA was isolated and linearly amplified and assayed by the Glyco-Gene chip. 
A, Summary of fold change of specific genes expression in CD8 T cell at day 8 
compared to those in naïve CD8 T cell. The function of ST6Gal I is to catalyze 
the addition of α2,6 sialic acids to galactose. SNA lectin binds α2,6Galβ1-
4GlcNAc. B, Time-course of ST6Gal I gene expression during CD8 T cell 
activation in vivo shows dramatically reduced expression. Right panel showed 
the SNA lectin binding of CD8 T cell populations. Splenocytes from uninfected 
(naïve) Tg P14 mice, or P14 x Thy1.1 chimeras on day 8 or day 150 post-
infection with 2x105 pfu LCMV-Armstrong i.p. were stained with DbGP33-41 
tetramer, CD8 mAb, and SNA lectin. Gating on antigen-specific CD8 T cells 
reveals high staining of SNA on naïve CD8 T cells (SNAhigh), low binding on day 
8 effector CD8 T cells (SNAlow), and both populations among memory cells, 
SNAhigh and SNAlow. C, SNA lectin bingding of CD4 T cell populations. 
Splenocytes from uninfected (naïve) mice, or C57BL/6 mice on day 8 or day 200 
post-infection with 2x105 pfu LCMV-Armstrong i.p. were harvested and 
stimulated with GP61-80 for 4-5 hours, stained with CD44, or CXCR5, or IFNγ, 
CD4 mAb, and SNA lectin. D, Cartoons showing experimental procedure of recall 
responses of SNAhigh versus SNAlow binding memory CD8 T cells. Memory 
Thy1.1+ CD8+ T cells were sorted for SNAhigh versus SNAlow binding (greater than 
95% purity, not shown) and equal numbers of SNAhigh, SNAlow, or total antigen-
specific CD8 T cells were adoptively transferred into naïve C57BL/6 mice and 
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mice were infected with 2x106 pfu LCMV clone 13 i.v. Control mice received no 
cells. On indicated days, mice were bled to obtain serum to assay viremia and 
PBMCs to assay T cell expansion. On day 5 and day 8, mice that received 
SNAhigh memory CD8 T cells showed lower viremia. E, Higher T cell expansion 





















































Figure 4. 2. Impaired viral-specific responses in ST6Gal I-deficient mice. 
C57BL/6 wildtype or ST6Gal I null mice were infected with 2x105 pfu LCMV 
Armstrong i.p. Single cell suspensions of the spleen were processed and stained 
with antibodies as indicated, plasma cells gating on CD138+B220+cells, germinal 
center (GC) B cells gating on PNAhigh Fas+ cell population of gated IgDlowB220+ 
cells. ELISPOT assay was used to determine the numbers of LCMV-specific IgM 
and IgG ASCs. On day 8 p.i. A, Total numbers of T and B cells as indicated were 
enumerated. B, Histogram overlay of indicated antibodies binding of DbGP33-
41CD8+ T cells. Blue histogram shows B6, and red histogram shows ST6Gal I-/-. 
Bar graphs show mean fluorescence of indicated antibodies binding in both 
groups of mice. C. FACS analysis of SLEC and MPEC in same mice. Contour 
dot plot shows SLEC (KLRG1high IL7low) and MPEC (KLRG1low IL-7high) 
populations. Total numbers of SLEC and MPEC and their ratios were 
enumerated in bar graphs. D, Kinetics of total numbers of antigen-specific CD8 
and CD4 T cells measured by FACS or ICS on indicated days. E, total numbers 
of antigen-specific CD8 T cell in Memory and recall response. Viral titer in the 
ovaries on day 3 mice challenged intravenously with 2 x 106 PFU vaccinia 
expressing the GP33-41 peptide of the LCMV viral protein. Grey bar shows naïve 

















Figure 4. 3. T-bet regulates St6gal1 expression. 
Gene expression analysis was performed on day 6 and 8 p.i. with LCMV 
Armstrong pooled WT and T-bet null effector cells gating on CD8+ and tetramer 
DbGP33-41 population by microarray. Fold change of St6gal1 expression in WT 
MPEC compared to that in WT SLEC (A). From left to right: T-bet-/- SLEC 












Figure 4. 4. Disrupted B cell follicle in ST6Gal I null mice following LCMV 
infection. 
Mice were infected with LCMV intraperitoneally or remained uninfected, and on 
day 8 p.i., spleens were isolated and frozen for immunofluorescence staining 






















Figure 4. 5. Impaired CD8 T cell expansion is cell intrinsic. 
P14 TCR transgenic mice congenic for Thy1.1 were bred to ST6Gal I null mice. 
A, Dot plot of splenocytes from ST6Gal I+/-xP14 and ST6Gal I-/-xP14 littermates 
labeled with CD8, DbGP33-41 MHC tetramer, and SNA lectin. 1x106 splenocytes 
from WT and ST6Gal I-/- TCR transgenic splenocytes were singly-(B) or mixed in 
a 1:1 ratio and co-transferred (C) into non-transgenic naïve C57BL/6 mice by tail 
i.v. injection and the recipient mice were infected with LCMV Armstrong the 
following day. At day 8 p.i., total number of transferred (donor) cells were 
quantified in the spleens of recipient mice by flow cytometry. Bar graphs show 
n=7 for WT and n=11 for KO for single transfer (middle panel) and n=5 fo WT 
and n=5 for KO for co-transfer (lower panel) D, 5x105 WT and ST6Gal I-/- TCR 
trangenic CD8 T cells were purified and labeled with CFSE and transferred into 
recipient C57BL/6 non-transgenic mice by tail i.v. injection. The following day, the 
recipient mice were infected with 2x105 pfu LCMV Armstrong i.p. or left 
uninfected. On day 3 p.i. CFSE intensity of LCMV antigen-specific CD8 T cells 





















Figure 4. 6. Similar recruitment and T cell activation, but delayed IL-2Rα 
expression of ST6Gal I-/- CD8 T cells. 
1x105 splenocytes from ST6Gal I+/-xP14 wildtype or ST6Gal I-/- xP14 TCR 
transgenic splenocytes were intravenously transferred into naïve C57BL/6 mice 
and the recipient mice were intravenously infected with LCMV Armstrong 4 hours 
later after transfer. Spleen cells were isolated and stained with antibodies on 
indicated time-points and analyzed by FACS.  A, the proportion of donor CD8 
Tcells was showed in Contour dot plot and quantified in bar graphs. The linear 
kinetics of the percent of donor CD8 T cells expressing elevated CD69 (B) and 
CD25 (C) in spleen of both groups of mice was measured by FACS analysis. 

















Figure 4. 7. IL-2/IL-2R signaling and surface expression is impaired in 
ST6Gal I-/- CD8 T cells. 
2 x 105 splenocytes from ST6Gal I+/-xP14 wildtype or ST6Gal I-/- xP14 TCR 
transgenic mice were transferred to 96-well plate and incubated with GP33-41 
(0.01µg/ml) peptide at 37 oC. A, Spleen cells clustered after 2 days incubation 
with peptide. Photos are taken under light microscope at 10x magnification. B, P 
roliferative response of spleen cells after incubation with GP33-41 at day 1, 2, 3. 
Viable cells from single or pooled from triplicate wells were counted and 
measured by FACS for live cell percent. For GP33-41+ IL-2 group, after 4 hours 
incubation with peptide, cells were transferred to another plate and washed 
peptide away with 10%RPMI 1640. Recombinant IL-2 was added to the wells at 
a concentration of 10000 U/ml. Cells incubated for another 20 hours and 
intracellularly stained with CD8, CD25 (C), and pSTAT5 (D) antibodies. For IL-2 
only group, recombinant IL-2 was added from the beginning. Cells incubated for 
24 hours, stained with antibodies and analyzed by FACS. Data are 
































As one of the most abundant post-translational modifications of peoteins, 
glycosylation can impact cellular signal transduction and functionality (Ohtsubo 
and Marth, 2006; Rudd et al., 2001). Glyco-phenotypic changes during immune 
responses have been described for decades (Galvan et al., 1998a; London and 
Horton, 1980; Onami et al., 2002) . However, their functional relevance is still 
unclear. ST6Gal I is a glycosyltransferase that catalyze the addition of sialic acid 
to galactose via α2,6-linkage to generate the Siaα2,6 structure (Hennet et al., 
1998). This enzyme is highly expressed on B and T lymphocytes (Hennet et al., 
1998). However, the role of this enzyme in adaptive immunity during a viral 
infection remains largely unexplored. In this study, we comprehensively 
interrogate the role of ST6Gal I in viral specific T and B cell responses. We also 
examined the pathogenic outcome in mice loss of this enzyme. 
 
The generation of Influenza-specific humoral responses is impaired in 
ST6Gal I-deficient mice 
 
We observed that SNA lectin binding, which indicate ST6Gal I expression or 
activity, remains at high levels on naïve B cells, plasma blasts, and germinal 
center B cells following viral infection (Figure 2.1). To understand the functional 
relevance of ST6Gal I expression in B cell immunity, we infected ST6Gal I-/- mice 
with influenza virus. We demonstrated that the absence of ST6Gal I results in 
decreased early influenza specific IgM and IgG levels in the serum, as well as 
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defective generation of influenza specific antibody secreting cells (Figure 2.2). 
These impairments are not due to reduced viral load or antigen availability in 
these mice as influenza virus replicates similarly in the lungs (Figure 2.4). In 
contrast to impairments in the generation of acute antiviral humoral responses, 
ST6Gal I-/- mice are able to establish antiviral humoral memory, with high levels 
of IgG antibodies after day 14 p.i. (Figure 2.2, 2.6).  
To determine whether the observed impairment of viral specific humoral 
responses were B cell intrinsic, we adoptively transferred purified B cells with or 
without ST6Gal I into B cell deficient mice and infected with influenza virus. The 
viral specific IgM response was significantly reduced in mice that received 
ST6Gal I-/- B cells, whereas the viral specific IgG response was comparable 
compared to mice that received ST6Gal I+/+ B cells (Figure 2.7).  These results 
indicate the expression of ST6Gal I by B cells, at least partially, is required for 
optimal antiviral humoral responses.  
 
ST6Gal I deficiency results in altered sialylation of IgG and IgA, and 
promotes IgA mesengial deposition following influenza infection 
 
Previously, we found that ST6Gal I-/- mice demonstrated impairments in the 
generation of early antiviral specific IgM and IgG responses (Figure 2.2), 
whereas humoral immunity was normally established (Figure 2.6). When we 
analyzed the influenza specific IgA responses, paradoxically, we discovered that 
although ST6Gal I-/- mice showed impaired early influenza specific IgA 
responses, by memory time-points the levels of total IgA, and influenza specific 
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IgA were elevated in the serum of immune ST6Gal I-/- mice following influenza 
infection (Figure 3.1).  
As increased IgA levels in serum is highly correlated with the occurrence of a 
human disease, IgA nephropathy (D'Amico, 2004). We then examined whether 
evidence of glomerulonephritis developed in immune ST6Gal I-/- mice following 
influenza infection. We found that although immune ST6Gal I-/- mice displayed 
normal gross pathology of the kidneys (Figure 3.1, Table 3.1), they showed 
increased IgG and IgA deposition in the kidney glomeruli (Figure 3.2, 3.5), which 
is a hallmark of IgA nephritis (D'Amico, 2004). We noted that aberrant 
glycosylation of antibody has been proposed to affect the development of IgA 
nephritis (Novak et al., 2008). We therefore analyzed the glycosylation of IgG 
and IgA. We found that ST6Gal I-/- mice showed abnormal glycosylation in the N-
glycans of both IgG and IgA, with a complete loss of terminal sialylation of N-
glycans in IgG, and reductions in sialylated N-glycans in IgA (Figure 3.3, 3.4). 
Taken together, these data suggested that ST6Gal I deficiency, together with 
influenza infection, may initiate IgA nephritis.   
 
ST6Gal I promotes rapid IL-2Rα surface expression, increasing early 
proliferation of terminal effector CD8 cells 
 
We have demonstrated that SNA lectin binding remained high on B cells during 
activation and differentiation (Figure 2.1). In contrast, we discovered that ST6Gal 
I was differentially expressed during CD8 T cell differentiation, associated with 
changes in SNA binding accordingly (Figure 4.1). To investigate the functional 
significance of this differential regulation of ST6Gal I, we infected ST6Gal I-/- mice 
and demonstrated significant impairments in the generation of viral-specific T and 
B cell responses in ST6Gal I-/- mice (Figure 4.2). To ascertain whether reduced 
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ST6Gal I-/- CD8 T cell expansion was due to cell intrinsic defects, we adoptively 
transferred CD8 T cell with or without ST6Gal I into recipient mice and viral-
specific responses were measured. We found that ST6Gal I-/- effector CD8 T cell 
displayed defective expansion and diminished proliferation (Figure 4.2, 4.5), 
indicating that lack of ST6Gal I by CD8 T cells led to defective expansion due to 
impaired CD8 T cell proliferation. Moreover, ST6Gal I-/- CD8 T cells skewed 
towards memory precursor cells, while terminal effector cell proliferation was 
dampened (Figure 4.2). When we examined the proliferation in more detail, we 
found that IL-2Rα surface expression was delayed in vivo on ST6Gal I-/- CD8 T 
cells (Figure 4.6). We provide evidence of this delayed IL-2Rα expression is 
likely due to defective IL-2/IL-2R signaling (Figure 4.7). These studies indicate 
that the intrinsic expression of ST6Gal I promotes the rapid surface expression of 
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